OnCore # RG1121054  
1 
 [STUDY_ID_REMOVED]  
An mHe alth Mood Management  Tool (Actify!) to Improve  
Population -level Cessation  
  
OnCore # RG1121054  
2 
  
 
FRED HUTCHINSON CANCER CENTER  
Current version: 6/13/202 2 
 
Version 1 6/11/2020  
Version 2  10/14 /2021  
Version 3  1/25/2022  
Version 4  6/13/2022  
 
 
Title of Protocol:  
An mHealth mood management tool to improve population -level cessation  
 
 
Investigators List:  
Jaimee Heffner, PhD  Associate  Member, FHCRC  (206) [ADDRESS_315485] Manager , FHCRC  (206) 667 -2428  
Biostatistician:  
Kelsey Baker  Cancer Center Biostatistical Shared Resource  ([PHONE_5393]  
 
SPONSOR : National Institute on Drug Abuse , Grant Number: 1R34DA050967  
  
OnCore # RG1121054  
[ADDRESS_315486] a pi[INVESTIGATOR_2268], randomized controlled trial (n=240) to test the 
primary outcome of treatment acceptability and secondary 
outcomes of efficacy a nd mechanism of change  at 8-week follow -
up for two  smartphone applications for smoking cessation: the 
novel Actify  app, which integrates Behavioral Activation 
Treatment for Depression (BAT -D) with US Clinical Practice 
Guidelines (USCPG)  vs. the National Ca ncer Institute’s  QuitGuide  
app, which is based on USCPG . Specifically, we will:  
a) compare the treatment groups on user satisfaction and 
app utilization  (treatment acceptability)  
b) preliminarily compare the effects of the interventions on 
30-day point prevalence smoking abstinence (efficacy) and 
behavioral activation (mechanism of change)c) determine 
whether there is evidence of differential efficacy in smokers 
with vs. without pr e-quit depressive symptoms  
Study Design  2-arm randomized controlled pi[INVESTIGATOR_2268] t rial with 1:1 parallel assignment  
Population  Adult smokers with and without depressive symptoms  
Primary Endpoints  Treatment acceptability:  
• Satisfaction (user satisfaction ratings  of the assigned app at [ADDRESS_315487] -randomization)  
• Utilization  (total number of log -ins to the assigned app at [ADDRESS_315488] -randomization)  
Secondary Endpoints  Treatment efficacy  (e.g., smoking abstinence) , changes in th eory -based 
mechanisms of change.  
 
Smoking abstinence outcomes :  
• Primary: Self -reported 30 -day point prevalence abstinence (PPA) 
from smoking at [ADDRESS_315489] -randomization  
• Secondary: Self-reported [ADDRESS_315490] -randomization ; Biochemically -confirmed [ADDRESS_315491] -randomization ; Self-
reported and biochemically confirmed [ADDRESS_315492] -randomization ; Self-reported and 
biochemically confirmed 30 -day PPA fr om cigarettes and other 
non-medicinal nicotine/tobacco products at 8 weeks and 6 months, 
including e -cigarettes  
 
 
 
OnCore # RG1121054  
4 
 Mechanisms of change  outcomes:  
• Change in behavioral activation from baseline to [ADDRESS_315493] -
randomization  
• Change in depressive symptoms fro m baseline to [ADDRESS_315494] -care  smoking cessation app (QuitGuide)  
Treatment Groups  2 arm; Actify vs QuitGuide  
Treatment Schedule  The treatment period is 8 weeks . Participants will be encouraged to use 
their assigned app as desired  during that time .  
Number of trial subjects  N=240  
Estimated duration of 
trial 21 months  
Duration of Participation  6 months  
 
 
  
OnCore # RG1121054  
5 
 ABBREVIATIONS  
 
BAT-D Behavioral activation therapy for depression  
PPA Point Prevalence Abstinence  
USCPG  US Clinical Practice Guidelines  
  
OnCore # RG1121054  
6 
 Table of Contents  
1.0 GENERAL INFORMATION  ................................ ................................ ................................ ................................ .... 9 
1.1 Protocol Title: An mHealth mood management tool to improve population -level cessation  ...............  9 
1.2 Sponsor Information: National Institute on Drug Abuse, Grant Number: 1R34DA050967  ...................  9 
1.3 Investigator Information: Jaimee Heffner, PhD, (206) 667 -7314  ................................ ..........................  9 
1.4 Contractors and Consultants for the Study (if applicable): ................................ ................................ .... 9 
2.0 INTRODUCTION TO THE PROTOCOL  ................................ ................................ ................................ .................  10 
2.1 Introduction  ................................ ................................ ................................ ................................ .........  10 
2.2 Clinical Data to Date  ................................ ................................ ................................ ............................  13 
2.2.3. Preliminary studies of mHealth apps for smoking cessation.  ................................ ................................ ..... 16 
2.3 Risks/Benefits  ................................ ................................ ................................ ................................ ...... 16 
3.0 PRE-TRIAL INTERVENTION [LOCATION_003]BILITY TESTING  ................................ ................................ ................................ . 17 
3.1 Objectives:  ................................ ................................ ................................ ................................ ...........  17 
3.2 Study Population:  ................................ ................................ ................................ ................................  17 
3.3 Study Design:  ................................ ................................ ................................ ................................ .......  17 
3.4 Estimated Accrual:  ................................ ................................ ................................ ...............................  18 
3.5 Eligibility:  ................................ ................................ ................................ ................................ ..............  18 
3.6 Registration  ................................ ................................ ................................ ................................ ..........  18 
3.7 Usability Testing Overview  ................................ ................................ ................................ ..................  18 
3.8 Participant Compensation  ................................ ................................ ................................ ...................  19 
3.9 Enrollment Procedures  ................................ ................................ ................................ ........................  19 
3.10 Assessments/Evaluations  ................................ ................................ ................................ ....................  20 
3.11 Analytical methods  ................................ ................................ ................................ ..............................  20 
3.12 Objective  ................................ ................................ ................................ ................................ ..............  20 
4.0 OVERVIEW OF CLINICAL TRIAL  ................................ ................................ ................................ ..........................  21 
4.1 Study Objectives  ................................ ................................ ................................ ................................ .. 21 
4.2 Study Population:  ................................ ................................ ................................ ................................  21 
4.3 Study Design  ................................ ................................ ................................ ................................ ........  21 
4.4 Estimated Accrual:  ................................ ................................ ................................ ...............................  22 
4.5 Name [CONTACT_790]/Funding Source:  ................................ ................................ ................................ ...... [ADDRESS_315495] REGISTRATION  ................................ ................................ ................................ ................................ .... 23 
7.0 TREATMENT PLAN  ................................ ................................ ................................ ................................ .............  23 
7.1 Treatment Plan Overview  ................................ ................................ ................................ ....................  23 
7.2 Description of the interventions  ................................ ................................ ................................ ..........  24 
OnCore # RG1121054  
[ADDRESS_315496] EVALUATION  ................................ ................................ ................................ ................................ ...... 26 
8.1 Data Collection Overview  ................................ ................................ ................................ ....................  26 
8.2 Enrollment Procedures.  ................................ ................................ ................................ .......................  26 
8.3 Assessments/On -Study Clinical Evaluations  ................................ ................................ ........................  [ADDRESS_315497] DISCONTINUATION OF ACTIVE TREATMENT  ................................ ................................ ......................  28 
10.0 CONCOMITANT MED ICATIONS  ................................ ................................ ................................ .........................  29 
11.0 ADVERSE EVENTS  ................................ ................................ ................................ ................................ ..............  29 
11.1 Adverse Events  ................................ ................................ ................................ ................................ .... 29 
11.2 Collection and reporting of AEs and SAEs  ................................ ................................ ............................  29 
12.0 DATA AND SAFETY MONITORING PLAN  ................................ ................................ ................................ ............  30 
13.0 DATA MANAGEMENT/CONFIDENTIALITY  ................................ ................................ ................................ .........  30 
14.0 STATISTICAL CONSIDERATION S ................................ ................................ ................................ .........................  31 
14.1 Study Design  ................................ ................................ ................................ ................................ ........  31 
 Primary/Secondary Endpoints/Hypotheses and Analytical Methods  ................................ ..................  31 
14.2  31 
14.3 Sample Size and Power  ................................ ................................ ................................ ........................  33 
14.4 Randomization  ................................ ................................ ................................ ................................ ..... 33 
14.5 Ethnic and Gender Distribution Chart: Projected Target Accrual  ................................ ........................  33 
15.0 INVESTIGATOR OBLIGATIONS  ................................ ................................ ................................ ...........................  34 
16.0 REFERENCES  ................................ ................................ ................................ ................................ ......................  34 
17.0 APPENDICES  ................................ ................................ ................................ ................................ ......................  42 
Appendix A:  ................................ ................................ ................................ ................................ ................................ .... 43 
Data & Safety Monitoring Plan  ................................ ................................ ................................ ................................ ...... 43 
DSMP Contents  ................................ ................................ ................................ ................................ ..............................  44 
1 Summary of the protocol  ................................ ................................ ................................ ................................ .. 45 
1.1 Brief description of the protocol  ................................ ................................ ................................ .........  45 
1.2 Primary and secondary outcome measures  ................................ ................................ ........................  45 
1.3 Inclusion/exclusion criteria  ................................ ................................ ................................ ..................  [ADDRESS_315498]  ................................ ................................ ................................ .. 47 
2.3 Target population distribution  ................................ ................................ ................................ .............  47 
3 Data management and analysis  ................................ ................................ ................................ ........................  48 
OnCore # RG1121054  
[ADDRESS_315499] to ensure the validity and integrity of the data  ................................ ..................  50 
4.2 Procedures to guarantee the accuracy and completeness of the data  ................................ ...............  50 
5 Regulatory issues  ................................ ................................ ................................ ................................ ..............  51 
5.1 Reporting mechanisms of AEs/SAEs to the IRB and NIDA  ................................ ................................ ... [ADDRESS_315500] Plan  ................................ ................................ ................................ ................................ ................  57 
Appendix B: Fraud Prevention Protocol  ................................ ................................ ................................ .........................  59 
 
 
  
OnCore # RG1121054  
[ADDRESS_315501] deadly drug in the US. The number of deaths annually from cigarette 
smoking (~480,000) is over three times greater than the number of alcohol -related deaths 
(~88,000) and drug overdoses per year (~52,000) combined. Helpin g current smokers to quit is a 
public health priority. There are numerous forms of assistance available, yet they all have 
suboptimal outcomes for a large group of smokers: those who experience depressive symptoms 
before or during a quit attempt. Prior to making a quit attempt, 40 - 55% of smokers report 
depressive symptoms. Because depressed mood and other forms of negative affect are also 
common nicotine withdrawal symptoms, mood management strategies have the potential to 
benefit a majority of treatment -seeking smokers. Indeed, our pi[INVESTIGATOR_259510] 83% of 
smokers interested in using a cessation app endorse mood difficulties as a barrier to  quitting.  
Behavioral activation therapy for depression (BAT -D) is a novel addition to standard smoking 
cessation interventions that can address depressive symptoms as a risk factor for treatment 
failure. Scientific premise : Two pi[INVESTIGATOR_259511] -powered ra ndomized, controlled trial 
support the efficacy of BA -based treatments for smoking cessation delivered in face -to-face 
format. Delivery through an mHealth app would make this treatment widely disseminable as a 
standalone public health intervention. There a re currently no BA - based mHealth treatments for 
smoking cessation with established efficacy.  
 
More detailed rationale can be found below in section 2.0.  
 
Overview of Study Design .  
This project involves  conduct ing a pi[INVESTIGATOR_2268], randomized controlled trial (n= 240) to test the primary outcome 
of treatment acceptability and secondary outcomes of efficacy and mechanism of change for the 
behavioral activation app (Actify) vs. the USCPG -based app for smoking cessation  (QuitGuide) . We will 
test the interventions usin g an [ADDRESS_315502] 6 -month follow -up data to assess long -term o utcomes.  
 
1.1 Protocol Title : An mHealth mood management tool to improve population -level cessation  
1.2 Sponsor Information : National Institute on Drug Abuse, Grant Number: 1R34DA050967  
1.3 Investigator Information : Jaimee Heffner, PhD, (206) 667 -7314  
1.4 Contractors and Consultants for the Study (if applicable) :  
Jennifer McClure , PhD ( Kaiser Permanente, Seattle );  
Stacey Daughters, PhD (University of North Carolina at Chapel Hill);  
Elisardo Becoňa Iglesias, PhD (University of Santiago de Compostela, Spain ) 
 
OnCore # RG1121054  
10 
  
2.0 INTRODUCTION TO THE PROTOCOL  
 
2.1 Introduction  
Cigarette smoking remains the leading preventable cause of death in the [LOCATION_002]. The number of 
deaths annually from cigarette smoking (~480,000) [1] is over three times greater than the number of 
alcohol -related deaths (~88,000) [2] and drug overdose s per year (~52,000) [3] combined. Only 6% of 
smokers each year are able to successfully quit [4]. Novel interventions are needed to target the key 
factors that maintain smoking.   
 
2.1.1 Problem:  Depression is prevalent and interferes with smoking cessation. Mood management 
treatments can help, but effective options accessible at the population level do not currently exist.  
 
2.1.1.a. Prevalence of depressive symptoms among smokers . The estimated p revalence of 
current (past 12 months) major depressive disorder among smokers is 11% [5]. Depressive symptoms 
that do not meet full criteria for a mood disorder are even more prevalent, particularly among 
treatment -seeking smokers. Among callers to a state  tobacco quitline, 41% reported current depressive 
symptoms on the Patient Health Questionnaire -9 (PHQ -9) [6]: 25% met criteria for a major depressive 
epi[INVESTIGATOR_259512] 16% reported depressive symptoms that fell below the diagnostic threshold 
[7]. We have found similarly high rates of depression among smokers enrolled in our trials of 
technology -delivered cessation treatments. In a recent trial of web -based Acceptance and Commitment 
Therapy (ACT) for smoking cessation [8], over half (56%) of the 263 7 study participants screened positive 
for depression on the Center for Epi[INVESTIGATOR_121671] (CES -D) [9] scale. Approximately 
40% of participants in a pi[INVESTIGATOR_259513] -delivered ACT [10] screened positive for depression. 
This high pr evalence of depressive disorders and symptoms observed among treatment -seeking 
smokers (i.e., 40 -55%) in both clinical and research settings likely reflects the greater difficulty of 
quitting for these smokers and consequently greater need for assistance.  
 
2.1.1.b.  Evidence that depressive symptoms have a negative impact on quitting is robust . 
Observational population [11, 12] and clinical studies [13] have shown that both mood disorder 
diagnoses and depressive symptoms predict a lower likelihood of long -term cessation. Quit rates for 
people with mood disorders are between 17% (for major depressive disorder) and 60% (for bipolar 
disorder) lower than for people without mood disorders [14 -17]. In smoking cessation trials, depressed 
mood at the time of a quit a ttempt predicts failure to quit smoking [7, 18 -21], as does emergence of 
depression and other forms of negative affect during the post quit period [22]. Data from our trial of 
group -delivered cessation therapy suggested that the odds of quitting are reduce d by 50% among 
smokers with depressive symptoms at the time of a quit attempt, even when they receive gold -standard 
treatment combining pharmacotherapy with intensive smoking cessation counseling [23]. Furthermore, 
a majority of treatment -seeking smokers e xpress concern about the impact of mood on their likelihood 
of quitting. Illustrating the pervasiveness of this concern among users of mHealth interventions, data 
from the first 1100 users of our SmartQuit smoking cessation app indicated that 83% of the us ers 
endorsed mood difficulties as an anticipated barrier to quitting [24]. A problem with the current 
standard treatment approach, as outlined in the US Clinical Practice Guidelines (USCPG) [25], is that it 
does not address depressive symptoms as a mechani sm that maintains smoking.  
 
2.1.2. Solution : A readily accessible mHealth app for smoking cessation grounded in evidence -based 
behavioral activation therapy for depression (BAT -D).  
OnCore # RG1121054  
11 
 2.1.2.a. mHealth apps for cessation are readily accessible and can be effe ctive.  Currently, 77% 
of US adults own smartphones [26], and ownership rates among smokers mirror those of the general 
population [27]. The proportion of smartphone owners using mHealth applications is steadily increasing 
[27], broadening potential reach o f mHealth apps for smoking cessation. From 2012 -2014, smoking 
cessation apps were downloaded to smartphones in the US over 3.2 million times [28, 29], which is 
substantially greater than enrollment in text messaging programs for smoking cessation (i.e., 14 0,000 
subscriptions/year [30]). In a 2014 survey, 15% of US smokers said that had previously downloaded an 
app for smoking cessation, and 43% indicated an intent to use a cessation app in the future [31]. Given 
the fast pace at which uptake of technology a nd technology -delivered interventions occurs, it is likely 
that these [ADDRESS_315503] level of income ($0 -$14,999/year), 
almost half (45%) of US smokers own smartphones [27], and evidence suggests that similar proportions 
of smokers across the socioeconomic spectrum use smartphone app s for smoking cessation [32]. 
Additionally, smartphone ownership is not associated with race or ethnicity either in the broader US 
population [26] or among cigarette smokers [27] and, as such, does not perpetuate racial/ethnic 
disparities in access to inte rventions delivered in this new modality (as opposed to healthcare settings, 
where there are racial ethnic disparities in access to  care). An increasing number of Americans —
particularly racial/ethnic minorities and low -income adults —are now relying exclusi vely on smartphones 
for Internet access (~20% of each group) [26], meaning that traditional web -based interventions for 
smoking cessation that are not optimized for small screens or repackaged as mHealth apps will become 
virtually unusable for large segmen ts of the population. As such, mHealth apps may have greater 
potential reach —including reach into tobacco -related health disparities groups —than both text message 
and web -based interventions as smartphones become an increasingly ubiquitous technology.  
Although a fully -powered effectiveness trial has yet to be completed, mHealth apps for smoking 
cessation have been evaluated in a number of pi[INVESTIGATOR_7602], demonstrating promising results for 
acceptability and quit rates as high as 45% [10, 33 -38]. However, the  literature base to support apps for 
smoking cessation is still emerging and currently includes only two randomized, controlled trials [10, 
34]—both of which are pi[INVESTIGATOR_259514], as expec ted for a pi[INVESTIGATOR_799], lack of a statistically significant difference between treatment groups, 
even where differences in quit rates would be clinically meaningful if replicated in a larger trial [10]. 
While the early results are promising, published pi[INVESTIGATOR_259515] a number of methodological limitations including lack of biochemical verification, few studies with 
active control groups, and no assessment of long -term outcome data. In the design of the proposed 
projec t, we address all of these methodological limitations of prior app studies.  
Although the literature on mHealth apps for smoking cessation are still in nascent stage, there is 
ample evidence from the broader literature on mHealth interventions for behavior change that apps can 
be effective for supporting improved health behaviors. Results of the most comprehensive review to 
date of mHealth interventions for health behavior change showed that the majority (17 of 23 studies 
meeting inclusion criteria) showed s tatistically significant effects of the mHealth app on the targeted 
health behavior [39].  
 
2.1.2.b. BAT-D is an efficacious, theory -based treatment for depression.  Content analyses of 
mHealth apps that are currently available for a variety of conditions (i ncluding over 400 for smoking 
cessation) have been repeatedly shown to adhere poorly to behavioral theory and evidence -based 
behavior change techniques [40 -43]. BAT -D is based on a well -supported behavioral conceptualization of 
depression as resulting from  inadequate positive reinforcement obtained from one’s environment for 
non-depressed behaviors [44, 45]. The primary goal of BAT -D is to increase engagement in positively 
OnCore # RG1121054  
12 
 reinforcing activities consistent with one’s values. These, in turn, are expected to increase positive affect 
and to reduce negative moods and avoidance behaviors [45]. Behavioral activation (BA) is a component 
of cognitive behavioral therapy (CBT), demonstrated in a seminal dismantling study by [CONTACT_259547] [46]. Given that BA is 
less complex than CBT, it is more disseminable at the population level. BAT -D’s disseminability is even 
greater given that it is a briefer form of the treatment that, like BA [47],  has demonstrated effectiveness 
as a treatment for depression [48, 49].  
 
2.1.2.c. Application of BA to smoking cessation improves quit rates.  Although the origins of BA 
are as a treatment for depression, this approach has particular relevance for cigarette smoking and its 
co- occurrence with depressive symptomatology. In accordance with reinforcement theory, 
maintenance of smoking as well as de pressed behaviors results in part from a lack of reinforcement for 
healthy, alternative behaviors [44]. In support of the theory, preliminary outcomes from an adult 
smoking cessation trial of combined counseling and pharmacotherapy indicated that participa nts who 
were abstinent at the end of an eight -week treatment demonstrated an increase in the level of 
alternative, smoke -free, rewarding activities during the course of treatment and evidenced a reduction 
in depressive symptoms [50].   
Evidence to date sugg ests that the integration of BA principles more broadly, and BAT -D 
specifically, into standard cessation counseling can significantly improve quit rates for (1) the general 
population of smokers (of whom an estimated 40 -55% will have depressive symptoms) [ 51], (2) smokers 
with depression [52], and, (3) smokers at high risk of either having or developi[INVESTIGATOR_9103] [53]. 
Evidence from a fully - powered, randomized, controlled trial [51] of a face -to-face, BA -based cessation 
intervention (n=110) compared with standard cessation (n=109) and a waitlist control group (n=56) for 
general population smokers (of which 40% had a history of depression treatment) provides evidence to 
support integrating BA with standard cessation treatments for improved cessation. In thi s trial, recently 
completed by [CONTACT_21123], Dr. Becoňa and colleagues, the two active treatment groups received 8 
weeks of hour -long group counseling. At end of treatment, biochemically -confirmed quit rates were 
superior in the BA condition (64.7%) rela tive to the standard counseling condition (45.9%, p=.008) and 
the waitlist control condition (5.4%. p=.001). The higher quit rates in the BA condition relative to 
standard counseling persisted across the 3 -month (38.2% vs. 22.9%, p=.045), 6 -month (30% vs. 18.3%, 
p=.273), and 12 -month follow -ups (30.0% vs. 18.3%, p=.302), albeit with some attenuation of the effect 
over time. A limitation of this study was that it was underpowered to detect  smaller but still clinically 
meaningful effects (e.g., absolute diffe rence of 12 percentage points between two behavioral 
interventions at long -term follow -up could readily be considered a meaningful difference [54]).  
In a proof -of-concept study conducted by [CONTACT_21123], Dr. MacPherson, smokers with 
depressive symptoms w ere assigned to receive either the BAT -D-based Behavioral Activation Treatment 
for Smoking (BATS; n= 35) or standard cessation treatment (ST; n=33), and both groups received 
nicotine patches.  Participants were assessed at baseline, throughout treatment, an d at 4, 16, and 26 -
week follow -ups for depressive symptoms and carbon -monoxide (CO) -verified 7 -day point prevalence 
abstinence. At the end of treatment, BATS participants were 2.1 times more likely to be abstinent (p< 
0.05) than ST participants (17.1% vs. 9.1%). As expected, abstinence rates declined over time in both 
groups, yet there remained a significant effect of BATS treatment at the 26 -week follow -up (14.3% vs. 
0.0%; p < 0.05). Participants receiving BATS also evidenced greater improvements in depres sive 
symptoms across the 26 -week follow -up period.  
Another pi[INVESTIGATOR_799] [53] showed promising results of a BATS -based cessation treatment for 
smokers recently hospi[INVESTIGATOR_259516] (CS) —a population with a high prevalence 
of depression. Participants received either the BATS -CS intervention (n=28) or an intervention using 
standard cessation counseling content (standard of care, or SC; n=31). Results of this feasibility trial 
OnCore # RG1121054  
[ADDRESS_315504] size 
for BATS -CS on smoking cessation was promising: OR=1.27 (95% CI=0.41 -3.93) for [ADDRESS_315505]. Daughters, and colleagues found that the BAT -D in-
person intervention resulted in superior biochemically -verified abstinence rates at 3 - (42% vs. 25%, 
OR=2.2, 95% CI=1.3 -3.7), 6 - (27% vs. 12%, OR=2.6, 95% CI=1.3 -5.0), and 12 -month (20% vs. 8%, OR=2.9, 
95% CI=1.3 -6.1) follow -ups relative to a contact -matched control condition [55]. While not necessarily 
generalizable to smoking cessation, these findings suggest that BAT -D can be an effective treatment for 
substance use disorders that share common causal and maintenance factors with nicotine dependence, 
including lack of reinforcement of alternative behaviors to substance use.  
 
2.1.3. Summary of significance.  Symptoms of depression, w hich are common among smokers, decrease 
the odds of quitting by 50%. This study addresses the important public health problem of low quit rates 
and resultant tobacco -related health disparities among smokers experiencing mood dysregulation. The 
proposed pro ject builds off of a growing body of literature supporting the value of behavioral activation 
as a component of cessation counseling.  Behavioral activation is a promising treatment approach for an 
mHealth cessation intervention because: (1) it has demonst rated long -term efficacy for promoting 
abstinence from tobacco and other substance use and shown promise for smoking cessation in the face -
to-face format [52, 53, 55], (2) its rationale, principles, and components are well -suited to translation 
into an app  (e.g., scheduling valued activities and tracking their completion), and, (3) it is theory -based 
[44]. A BAT -D-based treatment accessed through smartphones –where there have been steady increases 
in ownership rates among adults –represents a new opportunity for increasing the accessibility of 
evidence -based smoking cessation interventions. This work fits with NIDA Behavioral & Integrative 
Treatment research priorities: developi[INVESTIGATOR_259517], guided by 
[CONTACT_75780] -based mechan isms of change, and with a focus on co -occurring psychiatric symptoms and 
disorders. At present, randomized controlled trials of BAT -D-based cessation interventions have relied 
on face -to-face treatment, which would reach only 4 -6% of the 42 million smoker s in the US based on 
current utilization of the traditional treatment modalities of individual and group counseling [1, 4, 56]. 
To extend the reach of this promising new intervention to the estimated 32 million smokers with 
smartphones [1, 57, 58], the vas t majority of whom will not seek formal treatment, we propose to 
develop a BAT -D app for smoking cessation to provide smokers with an effective method of addressing 
depressive symptoms as a barrier to quitting.  
 
 
2.2 Clinical Data to Date  
 
2.2.1. Development o f the Actify app. With the support of a pi[INVESTIGATOR_259518] (PI: [INVESTIGATOR_259519]), we developed a working prototype of a smartphone app, Actify, 
that delivers BAT -D as part of a smoking cessation intervention. The app was cr eated following user -
centered design processes, including competitive analysis, focus groups, and usability testing of early 
and late prototypes, followed by a single -arm pi[INVESTIGATOR_4251].  
 
OnCore # RG1121054  
[ADDRESS_315506] reviewed depression apps curre ntly on the market to 
generate (via personal experience) and assess (via user comments in app stores) user sentiment toward 
them in relation to their design and functionality. Such information is useful for understanding desirable 
features for a new app as  well as “pain points” that a user may experience if Actify contained similar 
features. Example desirable features included a user interface that is easy to navigate, personalized, and 
with clear presentation of accessible community or national resources f or assistance with depression. 
Example pain points included multi -screen data input, incoherent gamification, and unclear indication of 
progress.  
 
2.2.1.b. Focus groups.  Two focus groups were conducted in October 2016 to assess potential 
users’ previous experience using depression apps (e.g., likes/dislikes); to develop user personas, the 
embodiment of a “typi[INVESTIGATOR_2855]” user or users, which is a common user -centered design stra tegy; to elicit 
ideas for valued activities in several life domains (e.g., relationships, health, leisure) that the app could 
suggest to the user; and to understand users’ associations between emotions and colors that might 
appear in the app. Participants expressed a desire for a flexible, customizable program that took into 
account the uncertainties of daily life and provided relevant mood -related suggestions, tracking of no 
more than 5 -10 basic emotions, and feedback on progress. Participants described mo od apps they used 
previously as “boring” and noted that addition of some humor or excitement would help keep them 
engaged, as would a light color palette that had positive, uplifting associations. Two distinct user 
personas were developed (one primary, one  secondary) to guide design decisions, and lists of common 
values and valued activities were generated for inclusion in the app.  
 
2.2.1.c.  Late prototype usability testing.   Based on users’ reactions to early prototypes, the 
study team decided to continue  developi[INVESTIGATOR_259520] B, the first version of Actify. The user experience 
(UX) design team, consisting of a UX researcher and two UX design interns, developed several iterations 
of Actify features revised on the basis of early prototype testing. The revise d version underwent three 
rounds of user testing between Jan [ADDRESS_315507] their ability to navigate the major app components of onboarding, values identification, 
activity scheduling, ac tivity tracking, calendar, progress, and resources as well as to assess user 
expectations and desires for app functionality. The programmed version of the app was completed by 
[CONTACT_3476]’s long -time partner, 2Morrow, in July 2017. For evaluation purpos es, Actify was 
developed as a native app for Apple’s iOS.  
 
2.2.1.d. Single -arm trial of a limited Actify app . Between November 2017 and June 2018 we 
conducted a single -arm pi[INVESTIGATOR_259521] -D component. 
Beca use the planned notifications and other components to support smoking cessation were not 
included in this early development phase due to budgetary constraints, participants used NCI’s 
SmokefreeTXT text messaging program alongside Actify to provide content similar to what would be 
included in the final app. Primary aims were to (1) obtain preliminary data on user engagement and 
satisfaction, and (2) evaluate effects on the target behavior of increased engagement in valued activities 
as well as smoking cessat ion and improved mood. To achieve these aims, we used a 6 -week evaluation 
period to evaluate both engagement and short -term efficacy.  
Major inclusion criteria were: (1) age 18 or older, (2) current smoker, averaging at least 5 
cigarettes/day for the last 30 days, (3) interested in quitting smoking in the next 30 days, (4) own an 
iPhone version 5 or higher, which is necessary to run the current version of the Actify app without 
technical problems, (5) experience downloading and using one or more apps on the ir iPhone, (6) screens 
positive for mild to moderate current depressive symptoms (PHQ -9 score 5 -19). Exclusion criteria were: 
(1) currently receiving other treatment for depression, including psychotherapy or medication, (2) 
OnCore # RG1121054  
15 
 current use of another depressi on app, (3) severe depression (PHQ -9 ≥ 20) (3) current suicidal ideation 
(PHQ -9 item 9 score > 1), (4) receiving other treatment for smoking cessation, and (5) previous use of 
the SmokefreeTXT program.  
Participants were recruited from the Seattle area prim arily via no -cost Craigslist ads (59% of 
sample) and paid Facebook advertisements (41% of sample). We screened 72 individuals to enroll 17 
participants in the single -arm trial, of whom 16 (94%) completed the in -person, 6 -week follow -up visit 
and are includ ed in the subsequent complete -case results. These participants were 56% men, 38% racial 
minority, and 25% Hispanic, with mean age of 36 (SD=10). There was strong engagement with the app: 
average number of logins per participant was 20 (SD=16). Average chan ge in depression on the PHQ -9 
was a 5 -point decrease from baseline (SD=6), which was a statistically significant improvement in 
symptoms (p=.009). Average change in Behavioral Activation for Depression Scale (BADS) overall scale 
scores and activation subsc ale scores (Bat -D’s theory -based change mechanism) were not statistically 
significant but were in the hypothesized direction: BADS total scores increased by 14 points, on average 
(SD=32; p=.09) and activation subscale scores increased by 4 points (SD=10; p =.17). The 7 -day point 
prevalence abstinence rate at follow -up was 31% (5/16), and the 30 -day PPA was 19% (3/16).  
Collectively, these results demonstrate (1) our ability to recruit and retain participants, (2) high 
engagement with the app, and (3) a promising signal for impact on theory -based change processes and 
cessation outcomes, which were descriptively higher for  Actify than for our ACT SmartQuit app among 
the subgroup of depressed smokers (31% vs. 23% for complete -case 7 -day PPA and 19% vs. 6% for 30 -
day PPA at short -term follow -up) and better than published quit rates of 7% for SmokefreeTXT alone 
[60]. Engagemen t was also higher for Actify than SmartQuit (average of 20 logins over 6 weeks for Actify 
vs. 12 logins over 2 months for SmartQuit). Preliminary quit rates also compare favorably to the previous 
trial of face -to-face BAT -D for depressed smokers (i.e., CO -confirmed, 7 -day PPA rate of 17% at end of 
treatment vs. 31% for Actify) conducted by [CONTACT_21123], Dr. MacPherson [52]. These promising 
findings warrant completing development of the Actify app, modifying it to improve usability, and 
evaluating the comp lete product in a controlled pi[INVESTIGATOR_4251].  
 
2.2.2. Next steps.   
Following our extensive development work to translate BAT -D into an engaging mHealth app format, the 
next step is to complete the development of Actify by [CONTACT_259548]. After completi on of this next stage of work, the fully developed 
Actify app will be ready for pi[INVESTIGATOR_259522] a preliminary estimate of its acceptability, 
efficacy, and effects on behavioral activation and depressive symptoms as the theory -based mechani sms 
of change for smoking cessation (see Figure 1 for development timeline). This plan is consistent with 
Stage Ia and Ib of the NIDA Behavioral Therapi[INVESTIGATOR_259523] [61] and with the aims of the 
NIDA R34 mechanism to support behavioral and integrat ive treatment development.  
 
Figure 1.  Progress to date toward development of a complete version of the Actify app and launch of a 
pi[INVESTIGATOR_4251].  
 
 
 
 

OnCore # RG1121054  
[ADDRESS_315508] —called 
SmartQuit —in 2013 (PI: [INVESTIGATOR_259524], Fred Hutchinson Cancer Research Center Hartwell Innovation Fund). We 
then conducted the first RCT comparing two smartphone apps for smoking cessation —SmartQuit vs. 
NCI’s Quit Guide. Based on previously successful methods for national recruitment in our trial of web -
based ACT [62], we recruited via Facebook ads, Google ads, and a press release developed by [CONTACT_259549]. These efforts yielded 738 participan ts screened, 400 eligible, 340 
consented, and 196 randomized (98 per arm). The recruitment sources were: 39% from Facebook ads, 
38% from press -release generated media, and 23% from other sources. To maximize outcome data 
survey completion, we followed a pr otocol that sequentially timed the administration of separate survey 
modalities until the survey was completed: first via the web, then by [CONTACT_756], and then by [CONTACT_2319]. 
Participants were compensated $25 for completing the survey.  The achieved outcome survey  
completion rate of 84%, much higher than the 54% typi[INVESTIGATOR_259525] - based cessation trials [63 -
68], provided confidence in the effectiveness of our follow -up survey methods for maximizing data 
retention. Retention did not differ between arms. Smar tQuit participants had higher engagement with 
their assigned app (p <.0001) and a descriptively higher quit rate than the QuitGuide app at [ADDRESS_315509] -randomization:13% (95% CI: 6% -22%) in SmartQuit vs. 8% (95% CI: 3% -16%) in QuitGuide.  
We developed the second version of the app (SmartQuit 2.0) in 2014 (PI: [INVESTIGATOR_259524], Washington 
State Life Sciences Development Fund). Using data from the trial of SmartQuit 1.0, we evaluated which 
features of the app were most used and how feature usage was associated with qu itting. Based on that 
analysis [69], the app was restructured to funnel users to the features that showed the strongest 
relationships with quitting. This method yielded an 8 -exercise program with a core feature that 
prompted users to track when they let an  urge pass —a major focus of the ACT exercises and a strong 
correlate of quitting in the SmartQuit 1.0 trial [69].  Relative to SmartQuit 1.0, we found that SmartQuit 
2.0 had better user satisfaction (84% vs. 59%), although the estimated quit rate was simila r (11% vs.13% 
achieved 30 -day PPA at 2 months).  
In 2016, we completed a major redesign of SmartQuit, now called iCanQuit, which is currently 
being evaluated in a large (n=2500) RCT (PI: [INVESTIGATOR_259524], R01CA192849). Development of iCanQuit 
incorporated lessons le arned from building SmartQuit 1.[ADDRESS_315510] content. 
Recently, our team developed and began pi[INVESTIGATOR_48124] a targeted version of iCanQuit for cancer patients 
who smoke (PI: [INVESTIGATOR_259524], CVS Moonshot Award).  
This preliminary work demonstrates that (1) we have acquired considerable experience 
developi[INVESTIGATOR_259526], including formative research to 
understand user needs and desires and on methods to increase engagem ent (e.g., gamification), (2) our 
iterative development process has proven effective for improving user satisfaction across app versions, 
and (3) our methods for conducting nationally -recruiting mHealth trials yield strong recruitment and 
retention outcome s. 
 
2.3 Risks /Benefits  
 
Potential Risks . Participants will be told that the study may involve the following risks and/or 
discomforts:  
 
Therapeutic risks include : (1) physical and psychological consequences of smoking abstinence, 
including nicotine withdrawal, and (2) the possibility that the intervention may not help the 
OnCore # RG1121054  
17 
 participant manage depressive symptoms and/or quit smoking. Participants will be informed of 
the discomfort associated with nicotine withdrawal, including common withdrawal symptoms, 
and that nicotine withdrawal may exacerbate some psychiatric symptoms (e.g., depressive 
symptoms).  
 
Research -related risks:  (1) the possibility that answering some questions may be emotionally 
upsetting, and (2) the possibility of breach of confidentiality. It is possible that some of the 
questions asked of participants may cause some emotional discomfort. For example, assessm ent 
of symptoms of depression may result in feelings of shame due to the stigma associated with 
mental health conditions. There is also a small risk of breach of confidentiality if participant 
data, either in electronic or hard copy form, were to be access ed by [CONTACT_259550].  
 
Potential Benefits of the Proposed Research to the Subjects and Others  
Subjects will be provided with information regarding potential benefits of participation in the study, 
including: 1) the possibility that the study interv entions might help them to quit smoking and manage 
their depressive symptoms, 2) access to a smoking cessation smartphone application at no cost.  
 
Importance of the Knowledge to be Gained  
This study involves pi[INVESTIGATOR_259527], if found to be effective in a larger trial that 
would be informed by [CONTACT_177612][INVESTIGATOR_4251], could have an enduring, positive impact on the low quit rates 
among smokers experiencing depressive symptoms. As such, the minimal risks associated with 
participation in the prop osed study are exceeded by [CONTACT_259551].  
 
3.0 PRE-TRIAL INTERVENTION [LOCATION_003]BILITY TESTING  
3.1 Objective s: 
3.1.[ADDRESS_315511] a ~9-
day diary study to  assess user satisfaction with the updated app and its 
components as well as program utilization (n=10) . 
 
3.2 Study Population :  
We will recruit 10 adult smokers , age 18 or older with two levels of depressive symptom severity based 
on PHQ -8 score --none/minimal  symptoms of depression (scores of 0 -4: n=5) and mild/moderate  
symptoms of depression  (scores of 5 -19; n =5)--who are interested in quitting smoking.  Participants will 
be recruited nationally via  one or more  recruitment strategies used successfully in our p revious studies: 
targeted Facebook ads, Craigslist ads in states with a high prevalence of smoking or racial/ethnic 
minority residence (to achieve the target 25% racial/ethnic minority representation in the sample), 
other free methods of advertising on the  Internet (e.g., Reddit, Twitter), ResearchMatch.org, and earned 
media generated by [CONTACT_259552] . 
3.3 Study Design:  
When a prototype of the complete Actify app is ready, we will conduct a diary study as a field -based 
evaluation of its usability. Usability is the extent to which an app can be easily navigated and understood 
by [CONTACT_28024]. Usability is a critical outcome of the Stage I  intervention development process, as low 
usability can undermine engagement with the int ervention [70] as well as its potential efficacy for 
smoking cessation [71].  
OnCore # RG1121054  
18 
 3.3.1 Primary Objective : Completed development of a n smartphone  application  for smoking 
cessation based on BAT -D. The Actify! app will be  easily navigated and understood by 
[CONTACT_259553] . 
3.4 Estimated Accrual:  
We estimate that our recruitment efforts will lead to 120 screened, 40 eligible and 10 enrolled. We 
estimate recruitment to take 3 weeks.  
 
3.5 Eligibility:  
3.5.1 Inclusion Criteria  
• age 18 or older  
• curren t smoker, averaging at least 5 cigarettes/day for the last 30 days  
• interested in quitting smoking in the next 30 days  
• experience downloading and using one or more apps on their smartphone  
• either screens negative (PHQ -8 score 0 -4) for depression ( n=5) or screens 
positive for mild to moderate current depressive symptoms (PHQ -8 score 5 -19; 
n=5)  
• willing and able to complete all study activities and to receive compensation by 
[CONTACT_2319]  
• comfortable reading and writing in English  
• have a mobile  data plan and/or access  to WiFi to support the use of  the Actify 
app 
• reside in the US  
 
3.5.2 Exclusion  Criteria  
• severe depression (PHQ -8 ≥ 20)  
• receiving other treatment for smoking cessation  
• employees/family of investigator or study center  
• member of the same household as another participant  
• woman who is pregnant or breastfeeding, or planning to become pregnant  
• having a Google voice number as their primary phone number  (due to 
association with fraudulent study entry attempts in our previous work)  
• currently in carcerated  
• participated in earlier studies to develop the Actify app   
3.[ADDRESS_315512] , Facebook , Twitter,  and Reddit . Initial screening for 
participation will be conducted via web -based survey  in MS Form s. Individuals deemed e ligible will be 
contact[CONTACT_259554]; individuals remaining eligible and 
interested will be invited to attend an online , video -based  onboarding  visit.  
3.7 Usability Testing Overview  
 
Figure 1. Usability Testing Study Flow Chart  
 
 
 
 Onbording 
online video 
meeting &  
Verbal 
consent  Access to 
Actify! 
Intervention  Brief check -in 
call at 
midpoint of 
the daily diary 
entries  Daily Diary 
entry for 7 
days, via MS 
Forms  Final exit 
interview   
OnCore # RG1121054  
[ADDRESS_315513] 
enrolled participants in d ownloading Actify to their personal phone. Participants will be instructed to 
use Actify for one week and to keep a daily diary to report on their usage of and satisfaction with the 
program. Daily diaries will follow a semi -structured format, including ass essments of when they used the 
app, what prompted them to open it, what features they accessed, and what their overall experience 
was like. They will also be asked about any technical difficulties encountered and about ease of 
navigation.  Following comple tion of the diary entries , they will be asked to attend a final debriefing 
session which will include a semi -structured exit interview to assess (a) usage and satisfaction with the 
app, and (b) the impact of Actify on their smoking, mood, and engagement in  valued activities.  
Participants will also complete the 10-item System Usability Scale  [72], a common method of evaluating 
the usability of software. The User Experience (UX) researcher will be responsible for conducting the 
diary study.  Full length of study participation will be ~[ADDRESS_315514] practices and usability testing of government funded 
cessation programs [73] and have been successfully implemented previously in our treatment 
development work . After the diary study, the UX Researcher and the UX Designer will work with the PI 
(Heffner) and consultants (Becoňa, McClure , and Daughters) to use data gleaned from the diary study to 
inform any needed changes to Actify’s content and structure as well as to address any technical 
difficulties experienced by [CONTACT_70513]. Based on prior work, the types of changes needed at this stage of 
development are typi[INVESTIGATOR_259528] (e.g., f ont size, color), changes to the wording of specific messages, or de -bugging new 
features (e.g., inactive buttons). The Moby [CONTACT_259555].  programming team will then make changes needed to 
improve the usability and/or content of the app. The final version of Actify , which will be developed 
after the diary study, and will be used in the pi[INVESTIGATOR_4265].  
3.8 Participant Compensation  
 
Participants will receive up to $150. Compensation will be pro -rated and dispersed as follows : 
 
• $10 for the baseline visit  
• $10 for mid -point chec k in 
• $40 for the final debriefing visit  
• $10 for each daily diary entry, up to $70 (for 7 days)  
• $20 bonus for completing all 7 diary entries  
 
3.9 Enrollment Procedures  
 
Participants will be recruited nationally  through online services (e.g., Facebook , Twi tter, Craigslist  and 
Reddit  advertisements ). Recruitment materials will direct potential participants to a web -based 
screening survey  on Microsoft Forms . The survey provides basic information about the study to allow 
individuals to choose whether or not to proceed, then assess basic eligibility criteria. Individuals who do 
not meet eligibility criteria will be provided with the following quit -smoking resources via e -mail ; the  
QuitGuide app and the 800 -QUIT -NOW ph one number to reach their state’s quitline.  
 
Phone screening & informed consent . Study staff will call individuals who are deemed potentially eligible 
based on the initial online screening. During this call, the purpose and procedures of the study will be  
OnCore # RG1121054  
[ADDRESS_315515] -protected access to the Actify! app 
and will receive assistance with downloading the app . During th is meeting, participants will also be 
asked about their motivation to quit smoking. The brief (10 -15 minutes) mid -study session call and the 
final exit interview will also be scheduled. After the onboarding meeting , study staff will email 
partic ipants their log -in credentials for the Actify app as well as the date and time of their mid-study 
feedback call and their final exit interview.  
 
3.10 Assessments/Evaluations  
 
Onboarding video call  (Day 1) :  Smoking level, motivation (importance and confidence) to change 
smoking habits and cost of smoking will be assessed.  
 
Daily diary entry ( Days 2 -8): Participants will be instructed to use Actify for one week and to submit  a 
daily diary to report on their u sage of and satisfaction with the program. Daily diaries will follow a semi -
structured format, including assessments of when they used the app, what prompted them to open it, 
what features they accessed, and what their overall experience was like. They wil l also be asked about 
the specific device and operating system they used to access the app, any technical difficulties 
encountered and about ease of navigation.  
 
Mid-study check in call  (Day 4 -5): the UX Researcher will connect briefly with each participa nt for a 10 –
15-minute check in about their experience and engagement with the Actify! app. Qualitative research 
notes will be taken during this call.  
 
Final exit interview  (Day 9 -10): Following completion of the diary study, participants will be asked to 
attend an online video meeting for a final debriefing session which will include a semi -structured exit 
interview to assess (a) usage and satisfaction with the app, and (b) the impact of Actify on their smoking, 
mood, and engagement in valued activities.  As part of the final exit interview, participants will complete 
the 10 -item System Usability Scale  [72], a common method of evaluating the usability of software. 
Participants will also be asked to report any technical difficulties they may have experienced.   
 
3.[ADDRESS_315516] the benchmark score of 68, which represents average usability.  
 
3.12 Objective  
 
The Acitfy! App will be  developed that can be easily navigated and understood by [CONTACT_28024] . 
OnCore # RG1121054  
21 
  
4.0 OVERVIEW OF CLINICAL TRIAL  
 
4.1 Study Objectives  
 
4.1.1 Primary Objectives:  Assess  and compare treatment acceptability across treatment 
arms.  
4.1.2 Secondary Objectives:  Preliminarily assess efficacy  and mechanism of change  for 
the behavioral activation app  (Actify)  vs. the USCPG app (QuitGuide)  for smoking 
cessation . 
4.1.3 Tertiary Objectives :  Determine whether there is evidence of differential efficacy in 
smokers with vs. without pre -quit depressive symptoms  
 
4.2 Study Population :  
We will recruit 240  adult smokers, both with (PHQ= 8 score 5 -19; n=120 ) and without (PHQ -8 score 0 -4; 
n=120) depressive symptoms, who are interested in quitting smoking.  Participants will be recruited 
nationally via recruitment strategies used successfully in our previous studies: targeted Facebook ads, 
Craigslist ads in states with a high prevalence of smoking or racial/ethnic minority residence (to achieve 
the target 25 % racial/ethnic minority representation in the sample), other free methods of advertising 
on the Internet (e.g., Reddit, Twitter), ResearchMatch.org, and earned media generated by [CONTACT_259556] . 
 
Inclusion of Women & Minorit ies.  
Our previous trials suggest that, without intervention to diversify the sample, the vast majority of 
participants would be Caucasian and female. To attain adequate representation of racial/ethnic 
minorities and men, we will cap enrollment of Caucasia ns and women at 75% of the sample via our 
online screening and enrollment process for the pi[INVESTIGATOR_4251]. We anticipate that these caps will be 
necessary and that the resulting sample will be 25% male and 25% racial/ethnic minority. If needed, we 
will use tar geted Facebook  and Twitter  campaigns specifically to recruit men and/or people with 
racial/ethnic minority affiliations (the ad platform’s proxy for race/ethnicity). Based on demographic 
data from our recent trial of a technology -delivered cessation interv ention using similar recruitment 
procedures [8], we expect the following percentages of racial minority participants: African American 
(10%), Native American or Alaska Native (2%), Native Hawaiian or Pacific Islander, Asian (2%), or 
other/multiple races (5 %). In terms of ethnicity, we expect 8% to identify as Hispanic or Latino.  
 
4.3 Study Design  
 
This is a  pi[INVESTIGATOR_2268], randomized controlled trial (n=240) to test the primary outcome of treatment 
acceptability and secondary outcomes of efficacy and mechanism of change  for the Actify app vs. the 
active control app (the National Cancer Institute’s  QuitGuide app). We will test the interventions using 
an [ADDRESS_315517] 6 -month follow -up data to assess long -term outcomes.  
 
4.3.1 Primary Endpoint s: Treatment acceptability as indicated by [CONTACT_259557]  (user satisfaction ratings of the assigned app at [ADDRESS_315518] -
OnCore # RG1121054  
22 
 randomization ) and app utilization ( total number of app server -recorded openings 
of the assigned intervention ) 
 
4.3.2 Secondary Endpoint s: Treatment efficacy (smoking cessation) and changes to 
theory -based mechanisms of change (behavioral activation).  
 
• Treatment efficacy:  
o Self-reported 30 -day point prevalence abstinence (PPA) from 
smoking at [ADDRESS_315519] -
randomization; Biochemically -confirmed [ADDRESS_315520] -randomization; Self -reported and 
biochemically confirmed [ADDRESS_315521] -randomization; Self -reported and biochemically 
confirmed 30 -day PPA from cigarettes and other non -medicinal 
nicotine/tobacco products at 8 weeks and 6 months, including e -
cigarettes  
• Mechanisms of change:  
o Change in behavioral activation from baseline to [ADDRESS_315522] -
randomization  
 
4.3.3 Exploratory Endpoints:  Differences in  treatment effects by [CONTACT_094] -quit depression 
(depressed vs. not depressed)  
4.4 Estimated Accrual :  
We estimate that our recruitments efforts will yield 904 screened, 490 eligible, 416 consented, and 240 
randomized int o the trial (120 per arm). We conservatively allotted 9 months for recruitment ( 26 
enrolled/month).  
 
4.5 Name [CONTACT_790]/Funding Source :  
National Institute on Drug Abuse , Grant Number: 1R34DA050967  
 
5.[ADDRESS_315523] ELIGIBLITY  
 
5.1 Inclusion Criteria  
• age 18 or older  
• current smoker, averaging at least 5 cigarettes/day for the last 30 days  
• interested in quitting smoking in the next 30 days  
• experience downloading and using one or more apps on their smartphone  
• either screens negative (PHQ -8 score 0 -4) for depression (n=120) or screens positive for 
mild to  moderate current depressive symptoms (PHQ -8 score 5 -19; n=120)  
• willing and able to complete all study activities  including  willing to receive  study 
compensation by  [CONTACT_2319]   
• comfortable reading and writing in English  
• have a mobile  data plan and/or access to WiFi to support the use of  the Actify app  
• reside in the US  
OnCore # RG1121054  
23 
 • have a smartphone  either an iPhone ( running iOS version 11 or higher) or an Android 
phone (running version 5.0 or higher)  
 
5.2 Exclusion  Criteria  
• currently receiving behavioral treatment for depression (e.g., psychotherapy)  
• current use of a depression app  
• severe depression (PHQ -8 ≥ 20)  
• receiving other treatment for smoking cessation  
• previous use of the QuitGuide program  
• current or recent (within the past year)  enrollment  in a Fred Hutch smoking cessation  
study  
• employees/family of investigator or study center  
• member of the same household as another participant  
• woman who is pregnant or breastfeeding, or planning to become pregnant  
• currently incarcerated  
• Is ineligible per fraud prevention protocol  
 
6.[ADDRESS_315524] potential participants to a recruitment website, which provides basic 
information about the study and a portal to the informed consent form, screening, and baseline surveys.  
 
For participants who screen eligible on the recruitment website and provide their email address, we will 
instantly send them an email (and two reminders over a 14 -day period) inviting them to complete a 
secured online survey to provide informed consent and complete the baseline assessment. Those not 
consenting and completing the online enrollment process within 14 days will be sent an email notifying 
them that they were not enrolled and providing both the QuitGuide app and the 1 -800-QUIT -NOW 
phone number to reach their state’s quitline. Both arms will be described as smartphone apps designed 
to assist with quitting and containing tools to improve mood.  
 
To address potential fraudulent responses to web -based screening surveys with compensation for 
participatio n, we will use the same methods used in our previous studies: CAPTCHA verification, 
ineligibility if the IP address was previously used or suspi[INVESTIGATOR_15665], and telephone contact [CONTACT_259558][INVESTIGATOR_259529] (e.g., very brief survey completion 
times or unusual patterns in email addresses). To further deter fraudulent attempts to enter the study, 
no compensation will be provided for completion of the  screening and baseline surveys.  
 
Participants complet ing th is process will be enrolled in the study. This information will be stored in a 
secure research database behind FHCRC firewall . See section 7.2 Enrollment Procedures for more 
details.   
7.0 TREATMENT PLAN  
 
7.1 Treatment Plan Overview  
 
 
 
 
OnCore # RG1121054  
24 
  
 
Figure 2. Study Flow Chart  
 
 
 
 
 
 
 
 
 
 
7.2 Description of the i ntervention s  
 
QuitGuide app.  QuitGuide was created by [CONTACT_6812]’s Smokefree team. It contains brief quit advice; a tool 
for tracking smokefree days and a statistics menu for viewing progress ; a tool for tracking cravings and 
receiving a brief, related tip in  response; a “Learn to Quit” feature with information on steps to prepare, 
cravings, withdrawal, slips, and staying smokefree.  QuitGuide also has a “Manage My  Mood” feature on 
the main pag e that gives it credibility as an intervention for smokers with depression, but with minimal 
expected efficacy due to the limited nature of the feature —i.e., recording a mood state and having the 
option to journal, call a friend, view photos and notes, or view a tip or distraction for handling difficult 
mood states. An example tip offered for handling negative affective states: “Distract. Do a crossword 
puzzle, play a game, or start a book that’s been gathering dust.”  
 
Actify.  Consistent with the BAT -D treatment  model, the core functions of the current version of Actify 
are: (1) introducing the user to the program by [CONTACT_259559] c essation, (2) helpi[INVESTIGATOR_259530] , important life areas and meaningful  activities associated with their  value s that will 
replace smoking habits  (e.g., reading to my children), (3) prompting the user to schedule meaningful 
activitie s and providing reminders to complete them  and, (4) visualizing overall progress toward meeting 
activity goals as well as the relationship between activities completed and mood. The app also contains  
tailored messages  for smoking status and activity compl etion and r esource section s with guidance for 
starting and maintaining a smoke free life.  To increase engagement, the user receives  daily tips , 
personalized feedback on  money saved by [CONTACT_259560]/quitting smoking, feedback o n activities 
completed,  inspi[INVESTIGATOR_259531] , user stor ies and quotes of ex-smokers  overcoming challenges, 
noticing the benefits of quitting and how behavioral activation helped them to improve their mood and 
quit smoking . User stories illustrating how values can be translated into ac tions were associated with 
cessation in our prior work [69].  To acknowledge and motivate continued progress , the user is able to 
earn  badges  for smoke  free streaks, usage of the app , and activity completion.  
In-app notifications  will be used to provide reminders to use the program, to track  daily smoking 
and activity completion , and to remind users of upcoming scheduled activities . We added  a Quit Guide 
section to the app,  similar to QuitGuide’s “Learn to Quit” menu , that it is a vailable for reference if users 
need on -demand assistance.  Portions of the QuitGuide are also presented as suggested reading on the 
users’ dashboard.  Content for the new Quit Guide  feature supports  users with setting and preparing for 
a quit date, learning  about medications to assist with quitting, managing cravings and other withdrawal 
symptoms, handling high -risk situations, staying motivated, and recovering from lapses . The addition of 
the Quit Guide  section  matches Actify to the NCI QuitGuide app on the  cessation content, allowing for 
stronger inferences about the specific effects of Actify’s BAT -D components   Informed  
Consent &  
Baseline 
Assessment  Access to Actify intervention & 
associated text messages  2-month 
Follow -up 
Assessment  Enrollment/  
Randomization  
Access to QuitGuide intervention 
& associated text messages  6-month 
Follow -up 
Assessment  
OnCore # RG1121054  
25 
  
 
Comparison of Actify and QuitGuide.  
 Actify  QuitGuide  
Treatment approach  Behavioral activation + USCPG  USCPG  
Cessation content description  Static quit guide, push notifications 
with reminders to track activities and 
smoking  Static quit guide, push notifications 
with tips for quitting  
Targeting (mood management)  In-depth , personalized based on user 
input into the in app tracking s ystem ; 
core function of app  Superficial, “manage my mood” 
feature  
Interactive tracking/progress features  Mood, activities , smoking level  Mood, craving  
Game elements for engagement  Badges (trophies) for progress  Badges (trophies) for progress  
 
7.3 Concomitant Medication  
Use of concomitant treatments for both tobacco cessation and depression will be assessed at each time 
point.  Individuals who report using self -report any other quit smoking treatment, including FDA -
approved quit smoking medications ( e.g., nicotine patch, nicotine gum, Zyban), during the screening 
phase will not be eligible to participate in the study. At the [ADDRESS_315525] 
information on up to two  collateral contacts.   At each follow -up, we will send reminder letters. The data 
collection protocol is as follows: Day -14: mai l a $2 pre -incentive letter (non -contingent incentives 
increase retention [86]) two weeks before the first online survey invitation; Day 0: First email invitation 
with link to online version of survey, with offer of $10 bonus for completing the survey with in 24 hours; 
Day 7: Second email invitation with link to online version of the survey; Days 10 to 18: Eight attempts to 
complete telephone version of survey (one call per day); Day 19: Send mailed version of the survey.  
Based on our WebQuit RCT trial exper ience (n=2,637), we estimate that this protocol will yield 89% data 
retention, and that 92% of respondents will complete the web -based version of the survey (68% within 
24 hours and 32% after 24 hours).  
 
7.5 Participant Compensation  
 
Participants will receive  up to $ 124 for participating in this study. Specifically, a t 2- and 6 -month follow -
ups, participants will receive compensation based on the following structure:  
• $2 in a pre -incentive letter  for each follow -up (for a total of $4 ) 
• $25 for each follow -up survey completed  in any modality ( for a total of up to $50) 
• $10 bonus for completing the follow -survey within 24 hours of  the initial email  invitation (for a 
total of up to $20) 
• $25 for completing saliva cotinine and smartphone application -based  carbon monoxide testing, 
if asked, after the 2 -month and the 6 -month follow -up study survey  (for a total of up to $50)  
Participants whose data are flagged for potential deception related t o study eligibility criteria (e.g., age, 
US residence) will be contact[CONTACT_259561].  If 
eligibility cannot be confirmed, participants will not be compensated.  
 
OnCore # RG1121054  
[ADDRESS_315526] EVALUATION  
 
8.1 Data Collection O verview  
 
Table 1. Phase II Pi[INVESTIGATOR_259532]  8-week 
follow -up 6-month 
follow -up  
Purpose  
PHQ -8 (8 items)  X X X X Eligibility, 
mechanism of 
change  
Other eligibility criteria (~11 
items)  X    Eligibility  
Demographics (~10 items)   X   Sample 
Description  
FTND (6 items)   X   Sample 
Description  
Treatment satisfaction (~8 items)    X  Acceptability  
Treatment preferences (~5 
items)   X    
Tobacco/Nicotine use (~12 
items)   X X X Efficacy  
Behavioral Activation for 
Depression Scale (25 
items)   X X X Mechanism of 
change  
Concomitant treatment (2 items)  X X X X Stratification, 
sensitivity 
analysis  
Total number of items  36 items  70 items  53 items  45 items   
Estimated duration  ~5-8 min ~10-15 min ~15-20min ~10-15 min  
 
8.2 Enrollment Procedures.  
 
The study recruitment website provides basic information about the study, FAQ, information about the 
study team and Fred Hutchinson Cancer Research Center  (FHCRC) , and a portal to the informed consent 
form, screening, and baseline surveys.  
 
We will use the identical enrollment method proven successful in our previous, remotely -conducted 
RCTs. Specifically, for participants who screen eligible on the recruitment website and provide their  
email address, we will instantly send them an email (and two reminders over a 14 -day period) inviting 
them to complete a secured online survey to provide informed consent and complete the baseline 
assessment. Those not consenting and completing the online  enrollment process within 14 days will be 
sent an email notifying them that they were not enrolled and provide both the QuitGuide app and the 
800-QUIT -NOW phone number to reach their state’s quitline.  
 
To address potential fraudulent responses to web -based screening surveys, we will use the same 
methods used in our previous studies: CAPTCHA verification, ineligibility if the IP address was previously 
used or suspi[INVESTIGATOR_15665], and telephone contact [CONTACT_259562][INVESTIGATOR_50519] (e.g., very brief survey completion times or unusual patterns in email 
addresses). To further deter fraudulent attempts to enter the study, no compensation will be provided 
for completion of the screening and baseline surve ys. 
 
OnCore # RG1121054  
[ADDRESS_315527] manager  (Edit Serfozo) with questions about the study (contact [CONTACT_259563] b e provided). The informed consent will be collected and stored in the secure database  behind 
FHCRC firewall . Participants who complete the enrollment process will receive a copy of the informed 
consent via email for future reference.  
 
Baseline Assessment . The baseline survey assesses demographics, smoking history and current smoking 
behaviors  the use electronic cigarettes, mechanisms of change, and potential treatment moderators. 
More details below in section 7.3. The baseline survey data will be collected  and stored in a research 
data base  behind FHCRC firewall .  
 
After completing  the baseline assessment, and first log -in, the participants will be randomized to receive 
either Ac tify or QuitGuide intervention . Randomization will be  stratif ied based  on sex assigned at birth , 
level of smoking  and the presence of pre -treatment depressive symptoms . 
 
Following the completion of the baseline and contact [CONTACT_259564] a  
text message with a link to their phone. Once this link is cl icked the study team will send a n email and a 
text message indicating that they are enrolled in the study. This email and text message will provide 
them with a link to the randomly assigned  intervention and login credentials.  If in 3 days the participant 
has not opened the app, they will receive a text message reminder.  If in 3 more days the participant has  
still not opened the app , study staff will reach out  by [CONTACT_259565].   
 
8.3 Assessments/ On-Study Clinical Evaluations  
 
A complete schedule of as sessments is provided in the table [ADDRESS_315528] for 
Nicotine Dependence (FTND) [75] will be administer ed to assess degree of physical dependence on 
nicotine. Living with a smoker and quit attempts in the last 12 months will also be assessed. The Patient 
Health Questionnaire -8 (PHQ -8) is a widely -used assessment of depressive symptoms that has 
demonstrated ability to detect symptom changes over time as a result of treatment [ 91]. The scale 
scores range from 1 to 2 4, with severity thresholds as follows: 5 -9=mild, 10 -14=moderate, 15 -
19=moderately severe, 20 -24=severe. A score of 10 has 88% sensitivity and 88% specificity for a 
diagnosis of major depression [6].  We elected to use the PHQ -8 rather than the PHQ -9 because (a) the 
suicidal ideation item on the PHQ -9, which is omitted from the PHQ -8, does not have a significant 
impact on the evaluation of depression severity, as the cut -off scores are  the same for both versions, (b) 
because it would be impractical to conduct follow -up suicidality assessments and referrals for all 
screening completers who endorse any suicidal thoughts , and (c) because there is no reason to believe 
that behavioral  interventions  for tobacco cessation  would increase the risk of suicidality  and therefore 
require ongoing monitoring of suicidality as a safety assessment . 
 
Treatment acceptability will be assessed at the 8 -week end -of-treatment follow -up using measures of 
treatment utilization and satisfaction. Treatment utilization will include number of logins to the assigned 
application, determined objectively using custom web site analytics  data. Consistent with our prior 
studies,  treatment satisfaction will be assessed with 8 items on the 8 -week outcome survey. Example 
OnCore # RG1121054  
28 
 items include, “Overall, how satisfied are you with your assigned program?”; and “How useful was your 
assigned program?” Follow -up questions will probe satisfaction  with specific components of the 
program (e.g. app content, app organization, push notification content, push notification frequency). 
These data are critical for making iterative improvements of the content and functionality of the app as 
it progresses th rough the development cycle.   
 
Efficacy for smoking cessation  will be self -reported 30 -day point prevalence abstinence (PPA) at [ADDRESS_315529] -randomization (“Have you smoked at all, even a puff, in the last 30 days?”), consistent our 
previous RCT of SmartQu it vs. QuitGuide for smoking cessation [10]. Secondary efficacy endpoints 
include: (1) [ADDRESS_315530] -randomization, (2) 7 -day PPA at 8 weeks and 6 months, and (3) 
no use of cigarettes and other non -medicinal nicotine/tobacco products at [ADDRESS_315531] [77]. However, we will confirm self -reported 
abstinence among those who report [ADDRESS_315532] -published expert recommendations on biochemical 
confirmation of tobacco use and abstinence  [90], our biochemical verification procedures will include 
both saliva cotinine testing as well as remote carbon monoxide (CO) monitoring using iCO Smokerlyzers.  
Both the cotinine tests and the Smoker lyzers will be sent to participants by [CONTACT_2319].  Participants will 
complete the CO testing on their smartphones using the iCO app and send results to the study team via 
email, using a function available within the app. We will also ask them to take a photo of  the cotinine 
test results and return it via email. Aside from analysis of minor tobacco alkaloids (anabasine/anatabine, 
which require a urine sample and laboratory testing that would not be feasible in a remotely -conducted 
trial), this combination of meth ods is the best available approach that is feasible in a trial of this nature 
for differentiating distinct forms of nicotine and tobacco use. In order to meet the definition of 
biochemically -confirmed smoking abstinence, only the CO testing must be negativ e (<6 ppm for CO[1]). 
For analysis of abstinence from all forms of nicotine and tobacco, the CO test must be negative and the 
saliva cotinine must be negative for all abstainers who do not report recent (past 72 hours) use of 
nicotine replacement therapi[INVESTIGATOR_014] . For those who report recent use of NRT, there is no feasible method of 
differentiating therapeutic use of nicotine from other forms of nicotine intake in this trial. We will report 
both self -reported abstinence and biochemically confirmed abstinence in a ll reports of study outcomes.  
 
Mechanisms of change will be assessed using the PHQ -8 for depression and the 25 -item Behavioral 
Activation for Depression Scale (BADS) [82], which was designed to assess activation as a treatment 
process targeted by [CONTACT_259566] -D. Ex ample items from the BADS scale include “I did something that was hard 
to do but it was worth it,” and “I made good decisions about what type of activities and/or situations I 
put myself in.”  
 
Other assessments. Use of concomitant treatments for both tobac co cessation and depression will be 
assessed at each time point.  Treatment preferences will be assessed with a single question and alcohol 
(AUDIT -C) will be assessed at baseline.  
 
9.[ADDRESS_315533] DISCONTINUATION OF ACTIVE TREATMENT  
Participants can choose to discontinue their participation in this study at any time for any reason.  
 
OnCore # RG1121054  
29 
 10.0 CONCOMITANT MEDICATIONS  
Use of concomitant treatments for both tobacco cessation and depression will be assessed at each time 
point. Individuals who repo rt using self -report any other quit smoking treatment, including FDA -
approved quit smoking medications (e.g., nicotine patch, nicotine gum, Zyban), during the screening 
phase will not be eligible to participate in the study. At the 2 and 6 -month follow -up assessment, 
participants will be asked about their use of FDA -approved quit -smoking and pharmacotherapy for 
depression. Initiating use of FDA -approved quit -smoking medications during the study is allowed.  
 
11.0 ADVERSE EVENTS  
 
11.1 Adverse Event s  
This is a low-risk study with no intervention agent/drug. Because this is a smoking cessation 
intervention, some participants may quit smoking cigarettes and may experience the physical and 
psychological consequences of smoking abstinence, such as nicotine withdrawa l symptoms. As part of 
the informed consent procedures, participants will be informed about potential nicotine withdrawal 
symptoms and effects of abstinence. The intervention provides strategies designed to cope more 
effectively with symptoms of nicotine w ithdrawal. Finally, participants will be given information on 
pharmacotherapy for smoking cessation (e.g., nicotine patch) and how to obtain these medications.  
11.[ADDRESS_315534] manager  and outcome assessors will monitor participants’ progress 
and responses to surveys for adverse events and protocol compliance. The study manager  will complete 
quarterly reports on participant progress and status, any adverse events, and any protocol deviat ions.  
 
Reporting . 
All study staff working on the trial will be trained and required to report all unexpected and adverse 
events to the project manager  and the Principal Investigator. A form will be available for this purpose. 
Adverse events beyond what wo uld be expected in the course of smoking cessation will be reported to 
the Fred Hutch’s IRB in accordance with Fred Hutch policy.   
 
Reporting SAEs . For AEs meeting the criteria for an SAE, regardless of attribution, the study 
coordinator will inform the Fred Hutch IRB per their reporting guidelines and will complete and 
submit a NIDA SAE report form within 7 2 hours of the reported event. Should additional 
information become available after the initial report, a revised report will be submitted as soon 
as possible . 
Reporting AEs that do not meet the criteria for SAE . All reported AEs will be collected and 
reported via the study’s electronic database. AEs that are expected will be summarized at the 
time of continuation review.  
Reporting UEs that do not meet  the criteria for AEs . The study team will report any UEs to the 
Fred Hutch IRB per their reporting guidelines.  Fred Hutch will report the UE to the sponsor in 
accordance with the protocol.  
 
OnCore # RG1121054  
30 
 Definitions  
In general, unexpected events (UEs) include any eve nt, adverse or otherwise, that was not described as 
part of the study risks. For this trial, an example of an unexpected event that is not adverse is a 
participant who has become very unhappy with trial procedures. Adverse events (AEs) are any untoward 
occurrence with a trial participant whether or not it can be considered to be related to their smoking 
cessation intervention. Examples of adverse events in this trial could include development or worsening 
of depression symptoms. Serious adverse events (SAEs ) include any AE that results in death, a real risk of 
dying, inpatient hospi[INVESTIGATOR_059], persistent or significant disability/incapacity, or AEs that require 
intervention to prevent permanent impairment or damage. In this trial, an example of a serious adv erse 
event would be a suicide attempt.  
 
Management of SAEs or other study risks  
UEs, AEs, and SAEs will be reported to the Principal Investigator [INVESTIGATOR_259533]. If there is any doubt as to whether an event qualifies as a UE, A E, or SAE, staff members will be 
trained and encouraged to err on the side of caution – and to bring the event to the Principal 
Investigator’s attention for review. The PI [INVESTIGATOR_259534], AEs, and SAEs.  
 
Attribution  
The Principal Inve stigator will decide if a UE should be classified as an AE. If an event is classified as an 
AE, further attribution will be determined, as follows:  
• Related – AEs that are definitely, probably, or possibly related to the intervention.  
• Not Related – AEs that are doubtfully related or clearly not related to the intervention.  
 
12.[ADDRESS_315535]  
weekly meetings with the study team to discuss study progress, including recruitment and retention, 
adverse events, and protocol adherence.  Detailed DSMP in included in Appendix A. 
 
13.0 DATA MANAGEMENT/CONFIDENTIALITY  
The investigator will ensure that data collected conform to all established guidelines. Each subject is 
assigned a unique subject number to protect subject confidentiality. Only Fred Hutch IRB -approved 
project staff will  have access to study data. All data will be maintained on a secure -access drive in 
permission -restricted folders only accessible to project staff. All workstations and servers are physically 
secured in locked offices, reside behind the Fred Hutch firewall , and fully participate in Windows NT 
security. The data study folder will be further safe -guarded against unauthorized access by [CONTACT_259567].  
In no case will patient identifiers or data be provided to any person or entity ou tside the IRB -approved 
project team. Protected health information will not be disclosed, copi[INVESTIGATOR_530], transmitted by [CONTACT_6968], or 
transmitted in total or in part to anyone not connected with the approved protocol and not approved by 
[CONTACT_259568]. We will lim it our acquisition of identifiable information to the minimum amount of 
information necessary to link subject data, obtain contact [CONTACT_259569], and 
collect pertinent data necessary to complete the study aims.   
Any data included in manuscripts or publications stemming from this study will be presented as 
aggregate data only, and in a way that no individual could be identified.  At the end of the study, after all 
manuscripts are published, all identifiable files and crosswalks will  be destroyed in accordance with Fred 
OnCore # RG1121054  
31 
 Hutch IRB policy (7 years after the end of the study). Electronic media used to store all data will be 
cleaned or destroyed so the data is not retrievable. As a result of these measures, we do not expect any 
invasion o f privacy or breach of confidentiality.  
 
When any study personnel are no longer a part of the research team, the PI [INVESTIGATOR_259535]’s 
access to all study data and notify the Fred Hutch Information Security Officer of such action.  
 
Online Surveys . The study database will be designed and maintained by [CONTACT_259570], kept behind FHCRC 
firewall. Only key study staff will have access to the  study database  system. All staff have received 
Human Subject Research and HIPAA training. All data will be sto red in a secure password protected 
computer folder, which only authorized research staff will have access to.  
Mailed Surveys . Numerous safeguards will keep hard copy data secure. All hard copy data will be kept in 
a locked file cabinet accessible only by a uthorized research staff.  
 
Actify and QuitGuide app-based  Intervention . Numerous safeguards will keep electronic data secure. A 
secure password is required to access computers at our site, and computer networks are on secured 
servers that meet or exceed federal confidentiality standards. Each participant will have access to th eir 
website protected with a login. All connections to this website will be made using the secure sockets 
layer (SSL). Participant data are maintained on a server in a locked server room at Fred Hutch. Full access 
to the server is restricted to two staff m embers of the Fred Hutch Public Health Sciences Information 
Technology (PHS -IT) group and the two staff members of Datatope Inc. Participants access their 
intervention app by [CONTACT_259571], which is hosted on a secure server. The L ogin 
server has no access to the study database. It can send login credentials and, upon successful login, it 
can receive the participant’s responses provided in the intervention app to questions related to smoking 
and values. No potentially identifying in formation is entered into the app by [CONTACT_2299]. All 
communication with the Actify and the QuitGuide app  occurs over Secure Sockets Layer (SSL). The 
intervention app stores participant usage data. The only participant identifier that will be transmitt ed to 
this database server will be their login id. The site only stores data related to site usage.  
 
 
14.0 STATISTICAL CONSIDERATIONS  
14.1 Study Design  
 
Randomized controlled 2 -arm pi[INVESTIGATOR_4251]  
14.2 Primary/Seco ndary Endpoints/Hypotheses and A nalytical Methods  
 
Data anal yses will be conducted using the intent -to-treat approach, except where otherwise indicated.  
 
Aim 1. Conduct a pi[INVESTIGATOR_2268], randomized controlled trial (n=240) to test the primary outcome of treatment 
acceptability and secondary outcomes of efficacy and mechanism of change for the two treatment 
groups: Actify vs. QuitGuide.  
 
 ENDPOINTS  
• The primary acceptabil ity endpoints  are number of app openings and overall satisfaction 
ratings.  
 
OnCore # RG1121054  
32 
 • For smoking cessation : 
o The primary endpoint is the 30 -day point prevalence abstinence (PPA) at [ADDRESS_315536] -randomization, which is comparable to the primary endpoints of the two 
extant trials of smartphone apps for smoking cessation [10, 34].  
o The secondary endpoints are 7 - and 30-day PPA at 6 months, 7 -day PPA at 8 weeks, 
and biochemically -confirmed abstinence from any nicotine/tobacco product (other 
than FDA -approved cessation medications) between baseline and 8 -week and 6 -
month follow -ups.  
 
• For mechanism of change ,  
o The prima ry endpoint is the change in BADS scores between baseline and the [ADDRESS_315537] for any demographic or other variables that differ 
between study arms at baseline and are related to outcome as well as the stratification factors 
(depression severity, sex assigned at birt h, and level  of smoking ). To compare binary endpoints 
between two arms (e.g.  smoking abstinence), a logistic regression model will be conducted with 
control for potential confounding variables and the stratification variable. Sensitivity analyses 
excluding participants using concomitant treatment for smoking cessation and/or depre ssion 
will also be conducted.  
 
Additional exploratory analyses will be conducted. To explore differential treatment effects by 
[CONTACT_094]-quit depression, we will preliminarily test the interaction of treatment group assignment 
and pre -quit depression and present  descriptive data on quit rates for the four subgroups 
(Actify, depressed; Actify non -depressed; QuitGuide, depressed; QuitGuide non -depressed). To 
evaluate the theory underlying BAT -D for smoking cessation, we will examine change in BADS 
scores between ba seline and 8 -week follow -up as a predictor of 30 -day PPA at 6 -month follow -
up using a logistic regression model. To generate empi[INVESTIGATOR_259536], we will evaluate the relationship between app “dosage” and cessation  
outcomes by [CONTACT_259572] 30 -day PPA at 8 weeks on objective measures of app utilization (e.g., 
number of app logins, total duration of use) using logistic regression. Similar to our feature 
analysis of SmartQuit that guided future app development [69], we w ill also regress 30 -day PPA 
at 8 weeks on utilization of specific app components (e.g., scheduling, mood tracking) to 
determine “active ingredients.” To evaluate the relationship between user characteristics and 
treatment utilization and outcomes, we will use logistic (for cessation outcomes) or negative 
binomial (for login count data) models and baseline data as predictors. To examine sex  as a 
biological variable, we will preliminarily test for sex differences in treatment response by 
[CONTACT_259573].  
 
Missing data:  Consistent with prevailing standards for smoking cessation trials [88], participants 
with missing smoking data will be considered non -abstinent in the primary analysis. As a 
sensitivity analysis, we will also re port abstinence rates from complete case analyses and 
multiple imputation. Treatment acceptability and mechanism of change (i.e., behavioral 
activation [BADS] and depression [PHQ -8] scores) will be analyzed using complete case analysis.  
OnCore # RG1121054  
33 
  
Modified intent -to-treat  approach . Because treatment acceptability is the primary outcome of 
this pi[INVESTIGATOR_4251], and because a valid assessment of acceptability is not possible in cases where 
there is pre -intervention attrition (i.e., never downloading or opening the assigned  app), we will 
use a modified intent -to-treat approach in which only those participants who open their 
assigned app at least once will be included in the outcome analyses.  
14.[ADDRESS_315538] feasibility [61]. However, as demonstrated in a recent simulation 
focused on sample size for pi[INVESTIGATOR_7602] [87], binary outcomes (e.g., smoking abstinence) require higher 
sample sizes for reasonable precision of the effect size estimate than do continuous outcomes. To be 
conservative, and in consideration of the higher recruitment capacity in remotely conducted studies 
involving standalone mHealth interventions, we chose to i nclude 60 subjects per arm within each 
stratum (depressed vs. non -depressed), as a sample size of [ADDRESS_315539] size estimates for binary outcomes [87]. Thus, each arm will have 120 participants, 
of wh ich 60 will meet criteria for mild to moderate depression.  
14.4 Randomization  
 
Following completion of the baseline survey, the web -based program will randomize participants to 
receive either Actify or QuitGuide with a 1:1 allocation ratio. The randomization algorithm will be 
developed by [CONTACT_15282], with stratificatio n by [CONTACT_259574] (PHQ -8 < 5 or PHQ -8 ≥ 5), sex assigned at birth  (2 levels: male or female) and level of smoking 
(2 levels: 20 or more cigarettes per day vs. < 20). Randomized participants will be emailed a secured link  
to download their assigned app. All participants will be emailed identical once -weekly reminders to use 
their assigned intervention.  Although we project, based on recent data from our trial of web -based 
interventions [8], that the vast majority (92%) of o utcome assessments will be completed via web -based 
survey, any outcome evaluator who has direct contact [CONTACT_259575] . 
 
 
 
14.5 Ethnic and Gender Distribution Chart : Projected Target Accrual  
Planned  
 
Racial Categ ories  Ethnic Categories   
Total   
Not Hispanic or Latino   
Hispanic or Latino  
Female  Male  Female  Male  
American Indian/ 
Alaska Native   2 0 0 6 
Asian  4 2 0 0 6 
OnCore # RG1121054  
[ADDRESS_315540] signs a form indicating their consent  to participate prior to receivin g any 
study -related procedures . 
 
 
16.0 REFERE NCES  
 
1. US Department of Health and Human Services. The health consequences of smoking --50 years of 
progress. A report of the Surgeon General. US Department of Health and Human Services 
CfDCaP, National Center for Chronic Disease Control and Prevention, Offi ce on Smoking and 
Health., editor. Atlanta, GA.2014.  
2. Centers for Disease Control and Prevention. Alcohol and public health: Alcohol -related disease 
impact (ARDI). Average for [LOCATION_002] 2006 -2010 alcohol -attributable deaths due to 
excessive alcohol use.  [cited 2017 September 30]. Available from: 
https://nccd.cdc.gov/DPH_ARDI/Default/Report.aspx?T=AAM&P=f6d7eda7 -036e -4553 -9968 - 
9b17ffad620e&R=d7a9b303 -48e9 -4440 -bf47 -070a4827e1fd&M=8E1C5233 -5640 -4EE8 -9247 - 
1ECA7DA325B9&F=&D.  
3. Rudd RA, Seth P, David F, Schol l L. Increases in Drug and Opi[INVESTIGATOR_2480] -Involved Overdose Deaths - 
[LOCATION_002], 2010 -2015. MMWR Morb Mortal Wkly Rep. 2016;65(5051):1445 -52. Epub 
2016/12/30. doi: 10.[ZIP_CODE]/mmwr.mm655051e1. PubMed PMID: 28033313.  
4. Centers for Disease Control and Prevention. Quit ting smoking among adults --[LOCATION_002], 
2001 - 2010. MMWR Morb Mortal Wkly Rep. 2011;60(44):1513 -9. Epub 2011/11/11. PubMed 
PMID: 22071589.  
5. Weinberger AH, Gbedemah M, Wall MM, Hasin DS, Zvolensky MJ, Chaiton M, et al. Depression 
Among Non -Daily Smokers Co mpared to Daily Smokers and Never -Smokers in the [LOCATION_002]: 
An Emerging Problem. Nicotine Tob Res. 2017. Epub 2017/03/25. doi: 10.1093/ntr/ntx009. 
PubMed PMID: 28339571.  
OnCore # RG1121054  
35 
 6. Kroenke K, Spi[INVESTIGATOR_4280], Williams JB. The PHQ -9: validity of a brief depression seve rity measure. J 
Gen Intern Med. 2001;16(9):606 -13. Epub 2001/09/15. PubMed PMID: 11556941; PubMed 
Central PMCID: PMCPMC1495268.  
7. Hebert KK, Cummins SE, Hernandez S, Tedeschi GJ, Zhu SH. Current major depression among 
smokers using a state quitline. Am J Pre v Med. 2011;40(1):47 -53. Epub 2010/12/15. doi: 
10.1016/j.amepre.2010.09.030. PubMed PMID: 21146767; PubMed Central PMCID: 
PMCPMC3006168.  
8. Bricker JB, Mull KE, McClure JB, Watson NL, Heffner JL. Improving quit rates of web -delivered 
interventions for smoking  cessation: full -scale randomized trial of WebQuit.org versus 
Smokefree.gov. Addiction. 2018;113(5):914 -23. Epub 2017/12/14. doi: 10.1111/add.[ZIP_CODE]. 
PubMed PMID: 29235186.  
9. Radloff LS. The CES -D Scale: A self -report depression scale for research in the gene ral 
population. Applied Psychological Measurement. 1977;1:385 -401.  
10. Bricker JB, Mull KE, Kientz JA, Vilardaga R, Mercer LD, Akioka KJ, et al. Randomized, controlled 
pi[INVESTIGATOR_9416] a smartphone app for smoking cessation using acceptance and commitment 
therap y. Drug Alcohol Depend. 2014. Epub 2014/08/03. doi: 10.1016/j.drugalcdep.2014.07.006. 
PubMed PMID: 25085225.  
11. Weinberger AH, Kashan RS, Shpi[INVESTIGATOR_259537], Esan H, Taha F, Lee CJ, et al. Depression and cigarette 
smoking behavior: A critical review of population -based studies. Am J Drug Alcohol Abuse. 
2017;43(4):416 -31. Epub 2016/06/11. doi: 10.3109/00952990.2016.1171327. PubMed PMID: 
27286288.  
12. Cooper J, Borland R, McKee SA, Yong HH, Dugue PA. Depression motivates quit attempts but 
predicts relapse: differential find ings for gender from the International Tobacco Control Study. 
Addiction. 2016;111(8):1438 -47. Epub 2016/02/19. doi: 10.1111/add.[ZIP_CODE]. PubMed PMID: 
26888199; PubMed Central PMCID: PMCPMC4940212.  
13. Stepankova L, Kralikova E, Zvolska K, Pankova A, Ovesna P, Bl aha M, et al. Depression and 
Smoking Cessation: Evidence from a Smoking Cessation Clinic with 1 -Year Follow -Up. Ann Behav 
Med. 2017;51(3):454 -63. Epub 2016/12/31. doi: 10.1007/s12160 -016-9869 -6. PubMed PMID: 
28035641; PubMed Central PMCID: PMCPMC5440483.  
14. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental 
illness: A population -based prevalence study. JAMA. 2000;284(20):2606 -10. Epub 2000/11/22. 
PubMed PMID: 11086367.  
15. Himelhoch S, Daumit G. To whom do psychiatrists offe r smoking -cessation counseling? Am J 
Psychiatry. 2003;160(12):2228 -30. Epub 2003/11/26. PubMed PMID: 14638595.  
16. Heffner JL, Strawn JR, DelBello MP, Strakowski SM, Anthenelli RM. The co -occurrence of 
cigarette smoking and bipolar disorder: phenomenology and treatment considerations. Bipolar 
Disord. 2011;13(5 -6):439 - 53. Epub 2011/10/25. doi: 10.1111/j.1399 -5618.2011.[ZIP_CODE].x. 
PubMed PMID: 22017214.  
17. Hitsman B, Papandonatos GD, McChargue DE, DeMott A, Herrera MJ, Spring B, et al. Past major 
depression and smokin g cessation outcome: a systematic review and meta -analysis update. 
Addiction.   
OnCore # RG1121054  
36 
 2013;108(2):294 -306. Epub 2012/10/18. doi: 10.1111/add.[ZIP_CODE]. PubMed PMID: 23072580; 
PubMed Central PMCID: PMCPMC3593055.  
18. Berlin I, Covey LS. Pre -cessation depressive mood predi cts failure to quit smoking: the role of 
copi[INVESTIGATOR_259538]. Addiction. 2006;101(12):1814 -21. Epub 2006/12/13. doi: 
10.1111/j.1360 - 0443.2006.[ZIP_CODE].x. PubMed PMID: 17156181.  
19. Cook J, Spring B, McChargue  D, Doran N. Effects of anhedonia on days to relapse among 
smokers with a history of depression: a brief report. Nicotine Tob Res. 2010;12(9):978 -82. Epub 
2010/08/17. doi: 10.1093/ntr/ntq118. PubMed PMID: 20709727; PubMed Central PMCID: 
PMCPMC2948830.  
20. Leve nthal AM, Ramsey SE, Brown RA, LaChance HR, Kahler CW. Dimensions of depressive 
symptoms and smoking cessation. Nicotine Tob Res. 2008;10(3):507 -17. Epub 2008/03/08. doi: 
10.1080/14622200801901971. PubMed PMID: 18324570; PubMed Central PMCID: 
PMCPMC2650807 . 
21. Leventhal AM, Pi[INVESTIGATOR_46746], Japuntich SJ, Baker TB, Cook JW. Anhedonia, depressed mood, and 
smoking cessation outcome. J Consult Clin Psychol. 2014;82(1):122 -9. Epub 2013/11/14. doi: 
10.1037/a0035046. PubMed PMID: 24219183; PubMed Central PMCID: PMCPMC393482 3. 
22. Kenford SL, Smith SS, Wetter DW, Jorenby [CONTACT_34479], Fiore MC, Baker TB. Predicting relapse back to 
smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol. 
2002;70(1):216 -27. Epub 2002/02/28. PubMed PMID: 11860048.  
23. Heffner JL, Mull KE, McClure JB, Bricker JB. Positive affect as a predictor of smoking cessation 
and relapse: Does it offer unique predictive value among depressive symptom domains? Subst 
Use Misuse. Accepted.  
24. Heffner JL. Smoking cessation app users' motivations, conc erns, and plans: profile of the first 
1100 users of SmartQuit. Society for Research on Nicotine and Tobacco Florence, Italy2017.  
25. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and 
dependence: 2008 update. Clinica l Practice Guideline. Rockville, MD: U.S. Department of Health 
and Human Services, Public Health Service; 2008.  
26. Mobile fact sheet [Fact sheet]. Pew Research Center; 2017 [cited 2017 April 14]. January 12, 
2017:[Available from: http://www.pewinternet.org/fa ct-sheet/mobile/.  
27. Heffner JL, Mull KE. Smartphone Ownership Among US Adult Cigarette Smokers: 2014 Health 
Information National Trends Survey (HINTS) Data. J Med Internet Res. 2017;19(8):e305. Epub 
2017/09/02. doi: 10.2196/jmir.7953. PubMed PMID: 28860108; PubMed Central PMCID: 
PMCPMC5599728.  
28. Estimated US downloads of smoking cessation apps since 2012 [updated March 24, 2014]. 
Available from: xyo.net.  
29. Fast growth of apps user base.: Portico Research; [updated March 26, 2014]. Available from: 
http://www.porti oresearch.com/en/blog/2013/fast -growth -of-apps -user -base -in-booming -asia-
pacific - market.aspx.  
30. Augustson E. Personal communication on estimated total number of US smoking cessation text 
messaging program subscribers since 2012. March 4, 2014.  
31. Borrelli B, B artlett YK, Tooley E, Armitage CJ, Wearden A. Prevalence and Frequency of mHealth 
and eHealth Use Among US and [LOCATION_006] Smokers and Differences by [CONTACT_259576]. J Med 
OnCore # RG1121054  
37 
 Internet Res. 2015;17(7):e164. Epub 2015/07/08. doi: 10.2196/jmir.4420. PubMed PMID: 
2614 9323; PubMed Central PMCID: PMCPMC4526978.  
32. Ubhi HK, Kotz D, Michie S, van Schayck OCP, West R. A comparison of the characteristics of iOS 
and Android users of a smoking cessation app. Transl Behav Med. 2017;7(2):166 -71. Epub 
2017/02/09. doi: 10.1007/s13142 -016-0455 -z. PubMed PMID: 28168609; PubMed Central 
PMCID: PMCPMC5526810.  
33. Bricker JB, Copeland W, Mull KE, Zeng EY, Watson NL, Akioka KJ, et al. Single -arm trial of the 
second version of an acceptance & commitment therapy smartphone application for smoking 
cessation. Drug Alcohol Depend. 2017;170:37 -42. Epub 2016/11/22. doi: 
10.1016/j.drugalcdep.2016.10.029. PubMed PMID: 27870987; PubMed Central PMCID: 
PMCPMC5183543.  
34. Buller DB, Borland R, Bettinghaus EP, Shane JH, Zimmerman DE. Randomized Trial of a 
Smartpho ne Mobile Application Compared to Text Messaging to Support Smoking Cessation. 
Telemed J E Health. 2013. Epub 2013/12/20. doi: 10.1089/tmj.2013.0169. PubMed PMID: 
24350804.  
35. Ubhi HK, Michie S, Kotz D, Wong WC, West R. A mobile app to aid smoking cessation: 
preliminary evaluation of SmokeFree28. J Med Internet Res. 2015;17(1):e17. Epub 2015/01/18. 
doi: 10.2196/jmir.3479. PubMed PMID: 25596170; PubMed Central PMCID: PMCPMC4319069.  
36. Iacoviello BM, Steinerman JR, Klein DB, Silver TL, Berger AG, Luo SX, et al. Cli ckotine, A 
Personalized Smartphone App for Smoking Cessation: Initial Evaluation. JMIR Mhealth Uhealth. 
2017;5(4):e56. Epub 2017/04/27. doi: 10.2196/mhealth.7226. PubMed PMID: 28442453; 
PubMed Central PMCID: PMCPMC5424127.  
37. Gordon JS, Armin J, M DH, Giacobb i P, Jr., Cunningham JK, Johnson T, et al. Development and 
evaluation of the See Me Smoke -Free multi -behavioral mHealth app for women smokers. Transl 
Behav Med. 2017;7(2):172 -84. Epub 2017/02/06. doi: 10.1007/s13142 -017-0463 -7. PubMed 
PMID: 28155107; PubMe d Central PMCID: PMCPMC5526811.  
38. Businelle MS, Ma P, Kendzor DE, Frank SG, Vidrine DJ, Wetter DW. An Ecological Momentary 
Intervention for Smoking Cessation: Evaluation of Feasibility and Effectiveness. J Med Internet 
Res. 2016;18(12):e321. Epub 2016/12/14.  doi: 10.2196/jmir.6058. PubMed PMID: 27956375; 
PubMed Central PMCID: PMCPMC5187451.  
39. Zhao J, Freeman B, Li M. Can Mobile Phone Apps Influence People's Health Behavior Change? An 
Evidence Review. J Med Internet Res. 2016;18(11):e287. Epub 2016/11/04. doi: 
10.2196/jmir.5692. PubMed PMID: 27806926; PubMed Central PMCID: PMCPMC5295827.  
40. Abroms LC, Lee Westmaas J, Bontemps -Jones J, Ramani R, Mellerson J. A content analysis of 
popular smartphone apps for smoking cessation. Am J Prev Med. 2013;45(6):732 -6. Epub 
2013/11/19. doi: 10.1016/j.amepre.2013.07.008. PubMed PMID: 24237915; PubMed Central 
PMCID: PMCPMC3836190.  
41. Abroms LC, Padmanabhan N, Thaweethai  L, Phillips T. iPhone apps for smoking cessation: a 
content analysis. Am J Prev Med. 2011;40(3):279 -85. Epub 2011/02/22. doi: 
10.1016/j.amepre.2010.10.032. PubMed PMID: 21335258; PubMed Central PMCID: 
PMCPMC3395318.  
OnCore # RG1121054  
38 
 42. Azar KM, Lesser LI, Laing BY, Stephens J, Aurora MS, Burke LE, et al. Mobile applications for 
weight management: theory -based content analysis. Am J Prev Med. 2013;45(5):583 -9. Epub 
2013/10/22. doi: 10.1016/j.amepre.2013.07.005. PubMed PMID: 24139771.  
43. Davis SF, Ellsworth MA, Payne HE, Hall SM, West JH, Nordhagen AL. Health Behavior Theory in 
Popular Calorie Counting Apps: A Content Analysis. JMIR Mhealth Uhealth. 2016;4(1):e19. Epub 
2016/03/05. doi: 10.2196/mhealth.4177. PubMed PMID: 26935898; PubMed Central PMCID: 
PMCPMC4795330.  
44. Hopko DR, Lejue z CW, Ruggiero KJ, Eifert GH. Contemporary behavioral activation treatments 
for depression: procedures, principles, and progress. Clin Psychol Rev. 2003;23(5):699 -717. Epub 
2003/09/16. PubMed PMID: 12971906.  
45. Lejuez CW, Hopko DR, Acierno R, Daughters SB, Pa goto SL. Ten year revision of the brief 
behavioral activation treatment for depression: revised treatment manual. Behav Modif. 
2011;35(2):111 -61. Epub 2011/02/18. doi: 10.1177/0145445510390929. PubMed PMID: 
21324944.  
46. Jacobson NS, Dobson KS, Truax PA, Addis  ME, Koerner K, Gollan JK, et al. A component analysis 
of cognitive -behavioral treatment for depression. J Consult Clin Psychol. 1996;64(2):295 -304. 
Epub 1996/04/01. PubMed PMID: 8871414.  
47. Ekers D, Webster L, Van Straten A, Cuijpers P, Richards D, Gilbody S . Behavioural activation for 
depression; an update of meta -analysis of effectiveness and sub group analysis. PLoS One. 
2014;9(6):e100100. Epub 2014/06/18. doi: 10.1371/journal.pone.0100100. PubMed PMID: 
24936656; PubMed Central PMCID: PMCPMC4061095.  
48. Dimidj ian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al. Randomized 
trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute 
treatment of adults with major depression. J Consult Clin Psychol. 2006;74(4 ):658 -70. Epub 
2006/08/03. doi: 10.1037/0022 - 006x.74.4.658. PubMed PMID: 16881773.  
49. Hopko DR, Lejuez CW, LePage JP, Hopko SD, McNeil DW. A brief behavioral activation treatment 
for depression. A randomized pi[INVESTIGATOR_259539]. Behav Modif. 
2003;27(4):458 -69. Epub 2003/09/16. doi: 10.1177/0145445503255489. PubMed PMID: 
12971122.  
50. Goelz PM, Audrain -McGovern JE, Hitsman B, Leone FT, Veluz -Wilkins A, Jepson C, et al. The 
association between changes in alternative reinforcers and short -term smoking cessation. Drug 
Alcohol Depend. 2014;138:67 -74. Epub 2014/03/07. doi: 10.1016/j.drugalcdep.2014.02.007. 
PubMed PMID: 24598122; PubMed Central PMCID: PMCPMC4030632.  
51. Martinez -Vispo C, Rodriguez -Cano R, Lopez -Duran A, Senra C, Fernandez Del  Rio E, Becona E. 
Cognitive -behavioral treatment with behavioral activation for smoking cessation: Randomized 
controlled trial. PLoS One. 2019;14(4):e0214252. Epub 2019/04/09. doi: 
10.1371/journal.pone.0214252. PubMed PMID: 30958831; PubMed Central PMCID: 
PMCPMC6453447.  
52. MacPherson L, Tull MT, Matusiewicz AK, Rodman S, Strong DR, Kahler CW, et al. Randomized 
controlled trial of behavioral activation smoking cessation treatment for smokers with elevated 
depressive symptoms. J Consult Clin Psychol. 2010;78(1): 55-61. Epub 2010/01/27. doi: 
10.1037/a0017939. PubMed PMID: 20099950; PubMed Central PMCID: PMCPMC3108050.  
OnCore # RG1121054  
39 
 53. Busch AM, Tooley EM, Dunsiger S, Chattillion EA, Srour JF, Pagoto SL, et al. Behavioral activation 
for smoking cessation and mood management followin g a cardiac event: results of a pi[INVESTIGATOR_48424]. BMC Public Health. 2017;17:323. doi: 10.1186/s12889 -017-4250 -7. 
PubMed PMID: PMC5392972.  
54. West R. The clinical significance of "small" effects of smoking cessation treatments. Addiction. 
2007;102(4):506 -9. Epub 2007/03/17. doi: 10.1111/j.1360 -0443.2007.[ZIP_CODE].x. PubMed PMID: 
17362283.  
55. Daughters SB, Magidson JF, Anand D, Seitz -Brown CJ, Chen Y, Baker S. The effect of a behavioral 
activation treatment for substance use on post -treatment abstinen ce: a randomized controlled 
trial. Addiction. 2018;113(3):535 -44. Epub 2017/10/01. doi: 10.1111/add.[ZIP_CODE]. PubMed PMID: 
28963853; PubMed Central PMCID: PMCPMC5807178.  
56. Shiffman S, Brockwell SE, Pi[INVESTIGATOR_134578], Gitchell JG. Use of smoking -cessation treatments  in the 
[LOCATION_002]. American Journal of Preventive Medicine. 2008;34(2):102 -11. Epub 2008/01/19. 
doi: 10.1016/j.amepre.2007.09.033. PubMed PMID: 18201639.  
57. Pew Internet Research Project. Mobile technology fact sheet 2013 [March 7, 2014]. Available 
from: http://www.pewinternet.org/fact -sheets/mobile -technology -fact-sheet.  
58. Heffner JL, Mull KE, McClure JB, Bricker JB. Positive Affect as a Predictor of Smoking Cessation 
and Relapse: Does It Offer Unique Predictive Value Among Depressive Symptom Domains? Subst  
Use Misuse. 2017:1 -9. Epub 2017/11/22. doi: 10.1080/10826084.2017.1387569. PubMed PMID: 
29161212.  
59. Barry MB, Saul J, Bailey LA. U.S. quitlines at a crossroads: utilization, budget, and service trends 
2005 - 2010. Phoenix, AZ: 2010.  
60. Augustson E, Cole -Lewis H , Sanders A, Schwarz M, Geng Y, Coa K, et al. Analysing user -reported 
data for enhancement of SmokefreeTXT: a national text message smoking cessation 
intervention. Tob Control. 2017;26(6):683 -9. Epub 2016/11/18. doi: 10.1136/tobaccocontrol -
2016 -052945. Pub Med PMID: 27852892.  
61. Rounsaville BJ, Carroll KM, Onken LS. A stage model of behavioral therapi[INVESTIGATOR_11482]: Getting 
started and moving on from stage I. Clinical Psychology: Science and Practice. 2001;8(2):133 -42. 
doi: 10.1093/clipsy/8.2.133. PubMed PMID: [ADDRESS_315541] Author & Affiliation: 
Rounsaville, Bruce J.  
62. Heffner JL, Wyszynski CM, Comstock B, Mercer LD, Bricker J. Overcoming recruitment challenges 
of web -based interventions for tobacco use: the case of web -based acceptance and 
commitment therapy  for smoking cessation. Addict Behav. 2013;38(10):2473 -6. doi: 
10.1016/j.addbeh.2013.05.004. PubMed PMID: 23770645; PubMed Central PMCID: 
PMC3725211.  
63. Berg CJ. Internet -based interventions for smoking cessation show inconsistent effects across 
trials, with only some trials showing a benefit. Evidence -based Nursing. 2011;14(2):47 -8. Epub 
2011/03/23. doi: 10.1136/ebn.14.2.47. PubMed PMID: 21421974.  
64. Civljak M, Sheikh A, Stead LF, Car J. Internet -based interventions for smoking cessation. 
Cochrane Database Syst Rev. 2010(9):CD007078. Epub 2010/09/09. doi: 
10.1002/14651858.CD007078.pub3. PubMed PMID: 20824856.  
OnCore # RG1121054  
40 
 65. Graham AL, Cobb NK, Papandonatos GD, Moreno JL, Kang H, Tinkelman DG, et al. A randomized 
trial of Internet and telephone treatment for smoking cessation. A rchives of Internal Medicine. 
2011;171(1):46 -53. Epub 2011/01/12. doi: 10.1001/archinternmed.2010.451. PubMed PMID: 
21220660.  
66. Hutton HE, Wilson LM, Apelberg BJ, Tang EA, Odelola O, Bass EB, et al. A systematic review of 
randomized controlled trials: Web -based interventions for smoking cessation among 
adolescents, college students, and adults. Nicotine Tob Res. 2011;13(4):227 -38. Epub 
2011/02/26. doi: 10.1093/ntr/ntq252. PubMed PMID: 21350042.  
67. Shahab L, McEwen A. Online support for smoking cessation: a syste matic review of the 
literature. Addiction. 2009;104(11):1792 -804. Epub 2009/10/17. doi: 10.1111/j.1360 -
0443.2009.[ZIP_CODE].x. PubMed PMID: 19832783.  
68. Webb TL. Commentary on Shahab & McEwen (2009): Understanding and preventing attrition in 
online smoking cessati on interventions: a self -regulatory perspective. Addiction. 
2009;104(11):1805 -6. Epub 2009/10/17. doi: 10.1111/j.1360 -0443.2009.[ZIP_CODE].x. PubMed 
PMID: 19832784.  
69. Heffner JL, Vilardaga  R, Mercer LD, Kientz JA, Bricker JB. Feature -level analysis of a novel 
smartphone application for smoking cessation. Am J Drug Alcohol Abuse. 2015;41(1):68 -73. 
Epub 2014/11/15. doi: 10.3109/00952990.2014.977486. PubMed PMID: 25397860; PubMed 
Central PMCID : PMCPMC4410684.  
70. Kalin S. Mazed and Confused 1999 [updated April 1, 1999Retrieved April 1, 1999]. Available 
from: http://www.cio.com/archive/Webbusiness/040199_use.html.  
71. Cheh JA, Ribisl KM, Wildemuth BM. An assessment of the quality and usability of smokin g 
cessation information on the Internet. Health Promot Pract. 2003;4:278 -87. 
72. Brooke J. SUS: A "quick and dirty" usability scale". In: Jordan PW, Thomas B, Weerdmeester BA, 
McClelland AL, editors. Usability Evaluation in Industry. London: Taylor and Francis ; 1996.  
73. Stoddard JL, Augustson EM, Mabry PL. The importance of usability testing in the development of 
an internet -based smoking cessation treatment resource. Nicotine Tob Res. 2006;Dec;[ADDRESS_315542] 
1:S87 -93. PMID: 17491175.  
74. Bricker J, Wyszynski C, Comstock B, Heffner JL. Pi[INVESTIGATOR_74636] -based 
acceptance and commitment therapy for smoking cessation. Nicotine & tobacco research : 
official journal of the Society for Research on Nicotine and Tobacco. 2013;15(10):1756 -64. Epub 
2013/05/25. do i: 10.1093/ntr/ntt056. PubMed PMID: 23703730; PubMed Central PMCID: 
PMC3768336.  
75. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine 
Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Ad diction. 
1991;86(9):1119 -27. 
76. Titov N, Dear BF, McMillan D, Anderson T, Zou J, Sunderland M. Psychometric comparison of the 
PHQ -9 and BDI -II for measuring response during treatment of depression. Cognitive Behaviour 
Therapy. 2011;40(2):126 -36. doi: 10.1080/ 16506073.2010.550059. PubMed PMID: [ADDRESS_315543] Author & Affiliation: Titov, Nickolai.  
OnCore # RG1121054  
41 
 77. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and 
cessation. Nicotine & Tobacco Research. 2002;4(2):149 -59. Epub 2002/0 5/25. doi: 
10.1080/14622200210123581. PubMed PMID: 12028847.  
78. Benowitz NL, Jacob III P, Ahijevych K, Jarvis MJ, Hall S, LeHouezec J, et al. Biochemical 
verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149 -59. 
79. Etter JF, Neidhart E, Bert rand S, Malafosse A, Bertrand D. Collecting saliva by [CONTACT_259577]. Eur J Epi[INVESTIGATOR_5541]. 
2005;20(10):833 -8. Epub 2005/11/12. doi: 10.1007/s10654 -005-2148 -7. PubMed PMID: 
16283473.  
80. Greeley  DA, Valois RF, Bernstein DA. Stability of salivary cotinine sent through the U.S. mail for 
verification of smoking status. Addict Behav. 1992;17(3):291 -6. Epub 1992/01/01. doi: 0306 -
4603(92)[ZIP_CODE] -S [pii]. PubMed PMID: 1636476.  
81. Jacob P, 3rd, Hatsukami D, S everson H, Hall S, Yu L, Benowitz NL. Anabasine and anatabine as 
biomarkers for tobacco use during nicotine replacement therapy. Cancer Epi[INVESTIGATOR_129859]. 2002;11(12):1668 -73. Epub 2002/12/24. PubMed PMID: 12496059.  
82. Kanter JW, Mulick PS, Busch AM, Berlin KS, Martell CR. The Behavioral Activation for Depression 
Scale (BADS): Psychometric properties and factor structure. Journal of Psychopathology and 
Behavioral Assessment. 2007;29(3):191 -202. doi: 10.1007/s10862 -006-9038 -5. PubMed PMID: 
2008 -[ZIP_CODE] -007. 
83. El-Hilly AA, Iqbal SS, Ahmed M, Sherwani Y, Muntasir M, Siddiqui S, et al. Game On? Smoking 
Cessation Through the Gamification of mHealth: A Longitudinal Qualitative Study. JMIR Serious 
Games. 2016;4(2):e18. Epub 2016/10/26. doi: 10.2196/games.5678. Pub Med PMID: 27777216; 
PubMed Central PMCID: PMCPMC5099502.  
84. Whittaker R, McRobbie H, Bullen C, Rodgers A, Gu Y. Mobile phone -based interventions for 
smoking cessation. Cochrane Database Syst Rev. 2016;4:Cd006611. Epub 2016/04/12. doi: 
10.1002/14651858.CD00661 1.pub4. PubMed PMID: 27060875.  
85. Whittaker R, McRobbie H, Bullen C, Borland R, Rodgers A, Gu Y. Mobile phone -based 
interventions for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD006611. Epub 
2012/11/16. doi: 10.1002/14651858.CD006611.pub3. PubMed  PMID: 23152238.  
86. Dillman DA. Mail and Internet Surveys: The Tailored Design Method. 2nd ed. Hoboken, NH: John 
Wiley & Sons, Inc.; 2007.  
87. Teare D, Dimairo M, Hayman A, Shephard N, Whitehead A, Walters S. Sample size requirements 
for pi[INVESTIGATOR_259540]: a simulation study. Trials. 
2013;14(S1):O21.  
88. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a 
common standard. Addiction. 2005;100(3):299 -303. Epub 2005/03/01. doi: ADD995 [ pii] 
10.1111/j.1360 - 0443.2004.[ZIP_CODE].x. PubMed PMID: 15733243.  
89. Muñoz RF, Lenert LL, Delucchi K, Stoddard J, Perez JE, Penilla C, et al. Toward evidence -based 
Internet interventions: A Spanish/English Web site for international smoking cessation trials. 
Nicotine & Tobacco Research. 2006;8(1):77 -87. Epub 2006/02/25. doi: 
10.1080/14622200500431940. PubMed PMID: 16497602.  
OnCore # RG1121054  
42 
 90. Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, Jarvis MJ, et al. Biochemical Verification of 
Tobacco Use and Abstinence: 2019 Update. Nicotine Tob Res. 2019. E pub 2019/10/02. doi: 
10.1093/ntr/ntz132. PubMed PMID: 31570931.  
91. Kroenke K, Strine TW, Spi[INVESTIGATOR_4280], Williams JB, Berry JT, Mokdad AH. The PHQ -[ADDRESS_315544]. 2009 Apr;1 14(1 -3):163 -73. doi: 
10.1016/j.jad.2008.06.026. Epub 2008 Aug 27. PMID: 18752852.  
 
 
17.0 APPENDICES  
 
Appendix A:  Data & Safety Monitoring Plan  
 
Appendix B: Fraud Prevention Protocol for Pi[INVESTIGATOR_4238]  
  
  
  
  
  
  
  
  
 
*Included in this protocol  document  for Scientific Review Committee, all other appendices will be 
provided for IRB submission  
 
 
 
  
OnCore # RG1121054  
43 
 Appendix A : Data  & Safety Monitoring Plan  
Version 2, 1/25/2022  
 
R34 DA050967  
 
“An mHealth mood management tool to improve population -level tobacco cessation ” 
 
PI: [INVESTIGATOR_259519], Jaimee L . 
OnCore # RG1121054  
44 
 DSM P Contents  
1 Summary of the protocol  3 
1.1 Brief description of the protocol  3 
1.2 Primary and secondary outcome measures  3 
1.3 Inclu sion/exclusion criteria  [ADDRESS_315545] to ensure the validity and integrity of the data  8 
4.2 Procedures to guarantee the accuracy and completeness of the  data…8    
5 Regulatory issues  10 
5.1 Reporting mechanisms of AEs/SAEs to the IRB and NIDA  [ADDRESS_315546] Plan  17 
OnCore # RG1121054  
45 
 1 Summary of the protocol  
1.1 Brief description of the protocol  
 
This study aims to inform the development of an app (Actify!) for smoking cessation that is grounded in 
behavioral activation therapy for depression (BAT -D). The primary aims are to (1) complete development 
of the new app by [CONTACT_259578], impro ving the app structure, conducting a 1 -week diary study 
to evaluate the app’s usability, and refining the app, and (2) c onduct a pi[INVESTIGATOR_2268], randomized controlled trial 
(n=240) to test the primary outcome of treatment acceptability and secondary outcomes of eff icacy an d 
mechanism of change for the Actify app vs. the active control app (the National Cancer Insitute’s 
QuitGuide app). We will test the interventions using an [ADDRESS_315547] 6 -month follow -up data to assess long -term 
outcomes.  
1.2 Primary and secondary outcome measures  
 
Acceptability outcomes:  
• Co-primary: User satisf action ratings of the assigned app at [ADDRESS_315548] -randomization  
• Co-primary: Total number of log -ins to the assigned app at [ADDRESS_315549] -randomization  
Smoking abstinence outcomes  
• Primary: Self -reported 30 -day point prevalence abstinence (PPA) from smoking at [ADDRESS_315550] -
randomization  
• Secondary:  
▪ Self-reported [ADDRESS_315551] -randomization  
▪ Biochemically -confirmed [ADDRESS_315552] -
randomization  
▪ Self-reported and biochemically confirmed [ADDRESS_315553] -randomization  
▪ Self-reported and biochemically confirmed 30 -day PPA from cigarettes and other non -
medicinal nicotine/tobacco products at 8 weeks and 6 months, including e -cigarettes  
Mechanisms of change  
• Co-primary: Change in behavioral activation from baseline to at [ADDRESS_315554] -randomization  
• Co-primary: Change in depressive symptoms from baseline to [ADDRESS_315555] -randomization  
1.3 Inclusion/exclusion criteria  
 
Inclusion criteria :  
• age 18 or older  
• current smoker, averaging at least 5 cigarettes/day for the last 30 days  
• interested in quitting smoking in the next 30 days  
• experience downloading and using one or more apps on their smartphone  
• either screens negative (PHQ -8 score 0-4) for depression ( Phase I n=5, Phase II n=120) or 
screens positive for mild to moderate current depressive symptoms (PHQ -8 score 5 -19; Phase I 
n=5, Phase II n=120)  
• willing and able to complete all study activities and willing to receive study compensation by  [CONTACT_259579] 
• comfortable reading and writing in English  
• have a mobile data plan and/or access to WiFi to support the use of the Actify app  
OnCore # RG1121054  
46 
 • reside in the US  
• have a sma rtphone either an iPhone (running iOS version 11 or higher) or an Android phone 
(running version 5.0 or higher)  
 
Exclusion  criteria :  
• currently receiving behavioral treatment for depression (e.g., psychotherapy)  
• current use of a depression app  
• severe depression (PHQ -8 ≥ 20)  
• receiving other treatment for smoking cessation  
• previous use of the QuitGuide program  
• current or recent (within the past year) enrollment in a Fred Hutch smoking cessation study  
• employees/family of investigator or study center  
• membe r of the same household as another participant  
• woman who is pregnant or breastfeeding, or planning to become pregnant  
• currently incarcerated  
• is ineligible per fraud prevention protocol  
1.[ADDRESS_315556] feasibility 1. However, as demonstrated in a recent simulation focused on 
sample size for pi[INVESTIGATOR_7602] 2, binary outcomes (e.g., smoking abstinence) require higher sample sizes for 
reasonable precision of the effect size estimate than do continuous outcomes. To be conservative, and in 
consideration of the high er recruitment ca pacity in remotely conducted studies involving standalone 
mHealth interventions , we chose to include 60 subjects p er arm within each stratum (depressed vs. non -
depressed), as a sample size of [ADDRESS_315557] 120 participants, of which 6 0 will meet criteria 
for mild to moderate depression.  
OnCore # RG1121054  
[ADDRESS_315558]              
Intervention              
Outcome assessment              
Data entry & quality control              
Data analysis              
Grant & manuscript 
preparation              
Note : Recruitment rate (~26 randomized/month) is feasible based on prior work and will prevent pi[INVESTIGATOR_259541].  
a Finalize survey instruments and recruitment materials; IRB application and approval ; build web -based study 
management system . 
2.[ADDRESS_315559] majority 
of participants would be Caucasian and femal e. To attain adequate representation of racial/ethnic 
minorities and men, we will cap enrollment of Caucasians and women at 75% of the sample via our online 
screening and enrollment process for the pi[INVESTIGATOR_4265]. We anticipate that these caps will be necessary and 
that the resulting sample will be 25% male and 25% racial/ethnic minority. Based on demographic data 
from our recent trial of a technology -delivered cessation intervention, we expect the following percentages 
of racial minority participants: African American (10%), Native American or Alaska Native (2%), Native 
Hawaiian or Pacific Islander, Asian (2%), or other/multiple races (5%).  In terms of ethnicity, we expect 
8% to identify as Hispanic or Latino.  
 
OnCore # RG1121054  
[ADDRESS_315560] advertisements in states with a high prevalence of 
smoking or racial/ethnic minority residence (to achieve the target 25% racial/ethnic minority 
representation in the sample), other free methods of advertisin g on the Internet (e.g., Reddit, Twitter), 
ResearchMatch.org, and earned media generated by [CONTACT_259552].  If 
needed, we will use targeted Facebook and Twitter ad campaigns specifically to recruit men and/or 
people with raci al/ethnic minority affiliations (the ad platform’s proxy for race/ethnicity).  
Our recruitment materials, which have now been used in two nationally -recruiting trials of web - 
and smartphone -delivered smoking cessation interventions (R01CA1 [ZIP_CODE] , R01CA192849 ), were 
developed in partnership with t he Dana Farber/Harvard University Health Communications C ore, which 
specializes in participant rec ruitment. They design ed our recruitment website , which provide s basic 
information about the study, FAQ, information about the study team and Fred Hutchinson Cancer 
Research Center (FHCRC), and a portal to the informed consent form, screening, and baseline surveys. 
They also assisted with the design and optimization of  online ads  (e.g., Facebook and Twitter ads) for 
referring potential participants to the recruitment website  and work ed with the FHCRC communications 
department on the design of press releases to be distributed over the course of the recruitment period.  All 
of these recruitment procedures and materials will be adapted for this trial. Similar to our other trials, we 
will program the recruitment website to limit non -minority recruitment to 75% and continue recruitment 
until the minority recruitment goal of at  least 25% is reached.  
We will use the identical enrollment method proven successful in our previous, remotely -
conducted RCTs. Specifically, for participants who screen eligible on the recruitment website and provide 
their email address, we will instantly  send them an email (and two reminders over a 14 -day period) 
inviting them to complete a secured online survey to provide informed consent and complete the baseline 
assessment. Those not consenting and completing the online enrollment process within 14 day s will be 
sent an email notifying them that they were not enrolled and provide both the QuitGuide app and the 800 -
QUIT -NOW phone number to reach their state’s quitline.  
To address potential fraudulent responses to web -based screening surveys, we will use the same 
methods used in our previous studies: CAPTCHA verification, ineligibility if the IP address was previously 
used or suspi[INVESTIGATOR_15665], and telephone contact [CONTACT_259580][INVESTIGATOR_50519] (e.g., v ery brief survey completion times or unusual patterns in email 
addresses). To further deter fraudulent attempts to enter the study, no compensation will be provided for 
completion of the screening and baseline surveys.  
 
3.1.[ADDRESS_315561] email, phone, and mailing address information . At each follow -up, we will send 
reminder letters . The data collection protocol is as follows: Day -14: mail a $2 pre -incentive letter (non -
contingent incentives increase retention 3) two weeks before the first online survey invitation; Day 0: First 
email invitation with link to online version of survey, with offer of $10 bonus for completing the survey 
within 24 hours; Da y 7: Second email invitation with link to online version of the survey; Days 10 to 18: 
Eight attempts to complete telephone version of survey (one call per day); Day 19: Send mailed version 
of the survey.  Based on our WebQuit RCT trial experience (n=2,637) , we estimate that this protocol will 
OnCore # RG1121054  
49 
 yield 89% data retention, and that 92% of respondents will complete the web -based version of the survey 
(68% within 24 hours and 32% after 24 hours). Participants will be compensated $[ADDRESS_315562] eted.  
3.2 Data entry methods  
All screening, baseline, and outcome survey data will be entered either directly by [CONTACT_259581] (for participants who complete the surveys by [CONTACT_87068]) 
into a study databas e managed by [CONTACT_259570], Inc.  
3.3 Data analysis plan  
Primary statistical review of the study will be conducted by [CONTACT_259582], 
guided by [CONTACT_079]. (See section 7 for detailed analysis plan).  
 
OnCore # RG1121054  
[ADDRESS_315563] access 
to their assigned app protected with a login. All connections will be made using the secure sockets layer 
(SSL).  
 
Participant data are maintained on a server in a locked s erver room at Fred Hutch. Full access to the 
server is restricted to two staff members of the Fred Hutch Public Health Sciences Information 
Technology (PHS -IT) group and the two developers of the study management system.  
4.2 Procedures to guarantee the accurac y and completeness of the data  
Data accuracy has two aspects in this trial: (1) accuracy of self -reported data by [CONTACT_259583], and (2) 
accuracy of data management. The trial has procedures for both, which will be reviewed annually by [CONTACT_259584].  
4.2.[ADDRESS_315564] manager  will monitor completeness  of data submitted by [CONTACT_259585] d surveys . Missing data  and data flagged for 
indication of inaccuracy (e.g., inconsistent dates of birth across surveys)  will be reviewed regularly and 
flagged for follow -up with study participants.  
4.2.2 Procedures during data transmission  
Forms used by [CONTACT_259586] -based forms. Data are maintained on a server in a 
locked server room at Fred Hutch. Full access to the server is restricted to two staff members of the Fred 
Hutch Public Health Sciences Information Technology (PHS -IT) group and  the two developers of the 
study management system.  
 
Project staff access the study database via the Study Management (SM) Web site. The SM Web site is 
only accessible from specific Internet Protocol (IP) addresses used by [CONTACT_464]. All communication with 
the SM Web site occurs over Secure Sockets Layer ( SSL). Both intervention arms will store participant 
usage data.  
4.2.[ADDRESS_315565] quality checks. 
Data quality will be assessed through a number of a nalytic methods. The study statistician will tabulate 
categorical variables with frequency counts, and for continuous variables we will examine descriptive 
statistics (mean, standard deviation, median, interquartile range, minimum, maximum), distributional  
characteristics (skewness, kurtosis, frequency histograms, normal probability plots), and associations 
(correlations, scatter plots).  Any free text or numeric values will be checked for accuracy, range 
consistency, and outlying values. We will examine al l missing response data to determine whether or not 
there are predictive characteristics that suggest the values are not missing at random and to determine 
whether imputation may be needed.  Data determined to be invalid based on apparent inaccuracies (e.g,  
two different dates of birth provided at different survey time points) that cannot be resolved via follow -up 
with participants will be excluded from the final dataset.  
OnCore # RG1121054  
51 
 5 Regulatory issues  
5.1 Reporting mechanisms of AEs/SAEs to the IRB and NIDA  
5.1.1 Reporting SAEs  
For AEs meeting the criteria for an SAE, regardless of attribution, the study coordinator will inform the 
Fred Hutch IRB per their reporting guidelines and will complete and submit a NIDA SAE report form within 
72 hours of the reported event.  Should additi onal information become available after the initial report, a 
revised report will be submitted as soon as possible.  
5.1.2 Reporting AEs that do not meet the criteria for SAE  
All reported AEs will be collected and reported via the study’s electronic database. AE s that are expected 
will be summarized at the time of continuation review.  
5.1.[ADDRESS_315566] officer.  
5.4 Trial stoppi[INVESTIGATOR_004]  
5.4.1 Complying with trial suspension reporting requirements  
Were the IRB or Clinical Trials Office  to issue a temporary or permanent suspension of the trial, the trial’s 
Principal Investigator s will immediately contact [CONTACT_20767]’s project officer , Will Aklin, Ph.D., National Institute 
on Drug Abuse, Division of Clinical Neuroscience & Behavioral Research, Behavioral and Integrative 
Treatment Branch, [ADDRESS_315567], Room 3182  Bethesda, Maryland [ZIP_CODE] -9551. Phone: 3 01-
443-4877 , Email: [EMAIL_4976] . 
5.[ADDRESS_315568].  
 
OnCore # RG1121054  
52 
 6 Trial safety  
6.1 Potential risks and ben efits for participants  
6.1.1 Risks of  intervention  and mitigation plan  
 
Therapeutic risks include: (1) physical and psychological consequences of smoking abstinence, including 
nicotine withdrawal, and (2) the possibility that the intervention may not help the pa rticipant quit smoking.  
Participants will be informed of the discomfort associated with nicotine withdrawal, including common 
withdrawal symptoms, and that nicotine withdrawal may temporarily exacerbate some psychiatric 
symptoms (e.g., depressive symptoms , which are part of nicotine withdrawal ) even though mental health 
has been extensively demonstrated to either remain unchanged or to improve by [CONTACT_259587] -up [4].   
 
Physical and psychological consequences of smoking abstinence, including  nicotine withdrawal.  
Participants will be informed about potential nicotine withdrawal symptoms. A rating scale  for depression 
(PHQ -8) will be administered at screening to assess eligibility and follow -up to assess intervention effects. 
Study staff completing telephone assessments and processing questionnaires returned by [CONTACT_259588] i f any suicidal ideation is spontaneously reported  by 
[CONTACT_4317] . All non -eligible individuals who complete the screening survey will receive an email 
containing other resources for depression assistance (including crisis line numbers) and cessation 
assis tance. Enrolled participants will receive crisis line information as part of their weekly emails with 
reminders to use their assigned program. Additionally, if a participant reports suicidal ideation at any time 
point, the participant will be evaluated by [CONTACT_978] [INVESTIGATOR_259542]. Participants 
will be told, as part of the informed consent process, that study staff will not be m onitoring self -report data 
in real time and that, should they experience suicidal thoughts during the study, they should seek 
assistance from a healthcare provider or crisis line.  
 
Possibility that the study interventions may not help the participant to qu it smoking.   Participants 
will receive information about the availability of alternative treatments to facilitate smoking cessation, 
including pharmacotherapi[INVESTIGATOR_259543], bupropi[INVESTIGATOR_2394], or varenicline; and 
counseling/support through telepho ne quitlines (1 -800-QUIT -NOW) or web sites like Smokefree.gov.  
6.1.2 Risks related to research procedures and risk mitigation plan  
Participants will be informed of the following research -related risks: (1) the possibility that answering 
some questions may be emotionally upsetting, and (2) the possibility of breach of confidentiality.  It is 
possible that some of the questions asked of participants may cause some emotional discomfort.  For 
example, assessment of symptoms of depression may result in feelings of shame due to the stigma 
associated with mental health conditions. There is also a small risk of breach of confidentiality if 
participant data, either in electronic or hard copy form, were to be accessed by [CONTACT_259550].  
 
All study personnel will receive required training in protection of human subjects in research as well as 
Good Clinical Practice training. Participants will be informed of therapeutic and research related risks as 
well as the safeguards and/or precautions taken to reduce these ris ks. The following procedures will be 
implemented to protect against the risks outlined above.  
 
Informed consent.   At the outset of the study, participants will be provided with detailed information 
about the study and provided with the opportunity to ask questions about study participation. Informed 
consent will be obtained following the guidelines of the Fred Hutch Institutional Review Board. 
Participants will be reminded that they are free to withdraw from the study at any point.  
 
OnCore # RG1121054  
[ADDRESS_315569] access to the assigned apps protected with a l ogin.  To address the possibility 
that individuals other than the participant might gain access to the participant’s phone, we will suggest 
that each participant password protect their phone to prevent unauthorized access.  
 
The study will be covered by a Certificate of Confidentiality from the National Institutes of Health to 
protect participants from involuntary disclosure of information collected as part of the study. Participants 
will be informed both verbally and in writing that the Certificate of Confi dentiality does not supersede 
federal and/or state laws governing exceptions to confidentiality (e.g., danger to self or others, mandated 
reporting of child or elder abuse/neglect). Similarly, participants will be notified that agents of the Fred 
Hutchinso n Cancer Research Center Institutional Review Board and the National Institutes of Health will 
be allowed to inspect sections of their study records, if requested. Otherwise, no information will be 
released to any individual or organization without their p rior written authorization. Subjects will be 
informed that the data from the study may be published; however, they will not be identified by [CONTACT_2300]. 
Subjects will be informed that their identity will remain confidential unless law requires such disclosure.  
6.1.3 Benefits of intervention  
It is possible that trial participants could quit smoking as a result of their participation. If so, the benefit to 
their short and long -term health would be significant.  
6.1.4 Benefits of research procedures   
Participation in the trial’s surveys will not offer any direct benefits,  but will advance knowledge in many 
important areas of adult smoking and smoking cessation. Participants may have a positive feeling about 
participating in this effort by [CONTACT_259589] e trial’s surveys.  
6.1.[ADDRESS_315570] manager and outcome assessors will monitor participants’ progress and 
responses to surveys for adverse events and protocol compliance. The project manager  will complete 
quarterly reports on participant progress and status, any adverse events, and any protocol deviations. 
Protocol adherence will be monitored by [CONTACT_079].  
6.2.[ADDRESS_315571] coordinator and the Principal Investigator. A form will be available for this purpose. Adverse 
events beyond what would be expected in the course of smoking cessation will be reported to the Fred 
Hutch’s IR B in accordance with Fred Hutch policy.  
OnCore # RG1121054  
54 
 6.2.3 Definitions  
In general, unexpected events (UEs) include any event, adverse or otherwise, that was not described as 
part of the study risks. For this trial, an example of an unexpected event that is not adverse is a 
participant who has become very unhappy with trial procedures. Adverse events (AEs) are any untoward 
occurrence with a trial participant whether or not it can be considered to be related to their smoking 
cessation intervention/NRT therapy. Examples of adve rse events in this trial could include development 
or worsening of depression symptoms. Serious adverse events (SAEs) include any AE that results in 
death, a real risk of dying, inpatient hospi[INVESTIGATOR_059], persistent or significant disability/incapacity, or  AEs 
that require intervention to prevent permanent impairment or damage. In this trial, an example of a 
serious adverse event would be a suicide attempt.  
6.3 Management of SAEs or other study risks  
UEs, AEs, and SAEs will be reported to the Principal Investi gator as soon as staff members are aware of 
them. If there is any doubt as to whether an event qualifies as a UE, AE, or SAE, staff members will be 
trained and encouraged to err on the side of caution – and to bring the event to the Principal 
Investigator’ s attention for review. The PI [INVESTIGATOR_259534], AEs, and SAEs.  
6.3.1 Attribution  
The Principal Investigator [INVESTIGATOR_259544] a UE should be classified as an AE. If an event is classified as an 
AE, further attribution will be determined, as fol lows:  
• Related – AEs that are definitely, probably, or possibly related to the intervention.  
• Not Related – AEs that are doubtfully related or clearly not related to the intervention.  
 
OnCore # RG1121054  
[ADDRESS_315572] of a comparison between two arms on three outcomes: acceptability, efficacy for 
smoking cessation, and effect on BAT -D theory -based mechanisms of change. The primary acceptability 
outcomes are number of app openings and overall satisfaction ratings.  For smoking cessation, the 
primary endpoint is self-reported 30 -day point prevalence abstinence (PPA) at [ADDRESS_315573] -
randomization, which is comparable to the primary endpoints of the two extant trials of smartphone apps 
for smoking cessation [10, 34]. The secondary endpoints are self -reported and bio chemically confirmed 7 - 
and 30 -day PPA at 6 months, 7 -day PPA at 8 weeks, and biochemically -confirmed abstinence from any 
nicotine/tobacco product (other than FDA -approved cessation medications) between baseline and 8 -week 
and 6 -month follow -ups. For mecha nism of change, the primary endpoint is the change in BADS scores 
between baseline and the 8 -week follow -up and the secondary endpoint is the change in depressive 
symptoms over the same time period.  
 
Linear regression will be used to evaluate treatment ef fects between the two arms for continuous 
endpoints (e.g, treatment satisfaction ratings). This model will adjust for any demographic or other 
variables that differ between study arms at baseline and are related to outcome as well as the 
stratification fac tors (depression severity, sex assigned at birth , and  heaviness of smoking ). To compare 
binary endpoints between two arms (e.g.  smoking abstinence), a logistic regression model will be 
conducted with control for potential confounding variables and the stratification variable. Sensitivity 
analyses excluding participants using concomitant treatment for smoking cessation and/or depre ssion will 
also be conducted.  
 
Additional exploratory analyses will be conducted. To explore differential treatment effects by [CONTACT_094] -quit 
depression, we will preliminarily test the interaction of treatment group assignment and pre -quit 
depression and present  descriptive data on quit rates for the four subgroups (Actify, depressed; Actify 
non-depressed; QuitGuide, depressed; QuitGuide non -depressed). To evaluate the theory underlying 
BAT-D for smoking cessation, we will examine change in BADS scores between ba seline and 8 -week 
follow -up as a predictor of 30 -day PPA at 6 -month follow -up using a logistic regression model. To 
generate empi[INVESTIGATOR_259545], we will evaluate the relationship 
between app “dosage” and cessation  outcomes by [CONTACT_259572] 30 -day PPA at 8 weeks on objective 
measures of app utilization (e.g., number of app logins, total duration of use) using logistic regression. 
Similar to our feature analysis of SmartQuit that guided future app development [69], we w ill also regress 
30-day PPA at 8 weeks on utilization of specific app components (e.g., scheduling, mood tracking) to 
determine “active ingredients.” To evaluate the relationship between user characteristics and treatment 
utilization and cessation outcomes , we will use logistic (for cessation outcomes) or negative binomial (for 
login count data) models and baseline data as predictors. To examine sex as a biological variable, we will 
preliminarily test for sex differences in treatment response by [CONTACT_259590].  
 
Missing data: Consistent with prevailing standards for smoking cessation trials [88], participants with 
missing smoking data will be considered non -abstinent in the primary analysis. As a sensitivity analysis, 
we wi ll also report abstinence rates from complete case analyses and multiple imputation. Treatment 
acceptability and mechanism of change (i.e., behavioral activation [BADS] and depression [PHQ -8] 
scores) will be analyzed using complete case analysis.  
OnCore # RG1121054  
[ADDRESS_315574]. Heffner will be responsible for monitoring the trial.  
8.2 Frequency of DSM reviews  
Data will be reviewed in the course of the trial on a quarterly basis. A full DSM report will be generated 
annua lly. 
8.3 Content of DSM report  
The content of the annual DSM report will follow this structure: (1) Brief description of the trial, (2) 
Baseline sociodemographic characteristics, (3) Retention and disposition of study participants, (4) Q.A. 
issues, (5) Regulat ory issues, (6) AEs, (7) SAEs, (8) Efficacy. A copy of this report will be provided to the 
NIDA project officer annually.  
OnCore # RG1121054  
[ADDRESS_315575] Plan  
A DSMB is not needed for this low -risk, single -site trial of two behavioral interventions for smoking 
cessation.  
OnCore # RG1121054  
58 
 References  
 
1. Rounsaville BJ, Carroll KM, Onken LS. A stage model of behavioral therapi[INVESTIGATOR_11482]: Getting 
started and moving on from stage I. Clinical Psychology: Science and Practice. 2001;8(2):[ADDRESS_315576] N, Whitehead A, Walters S. Sample size requirements 
for pi[INVESTIGATOR_259546]: a simulation study. Trials. 
2013;14(S1):O21.  
3. Dillman DA. Mail and Internet Surveys: The Tailored Desi gn Method.  2nd ed. Hoboken, NH: John 
Wiley & Sons, Inc.; 2007.  
4.  Taylor G, McNeill A, Girling A, Farley A, Lindson -Hawley N, Aveyard P et al. Change in mental 
 health after smoking cessation: systematic review and meta -analysis BMJ 2014; 348 :g1151 
 doi:10.1136/bmj.g1151  
  
OnCore # RG1121054  
59 
 Appendix B : Fraud Prevention Protocol  
 
ANTI -FRAUD PROCEDURES  FOR STUDY ENTRY  
 
OnCore # RG1121054  
60 
  

OnCore # RG1121054  
[ADDRESS_315577] -enrollment:  
 
1. Datatope  will create post -enrollment flags on data validity, including (a) inconsistency between 
outcome surveys and screening/baseline surveys in date of birth,  (b) multiple IP addresses/non -
US IP addresses detected post -enrollment   
2. Post -baseline manual checks f or address and IP address . 
3. Depending on level of evidence for fraud a participant could be flagged  and contact[CONTACT_235868]. Let them know that, before they can be compensated for their participation, we 
need to verify that some the information that they  provided is correct.  
4. Ask for full name [CONTACT_3816].  If different than what they provided previously, ask if they may 
have provided any other name [CONTACT_259592].   
5. Ask for their date of birth, current age, gender, and race and e thnicity. If gender or 
race/ethnicity are different than what they provided previously, ask if they may have provided 
any different response on a survey.  
6. After completing the call, check information provided against survey data. If there is clear 
evidence of deception (e.g, different dates of birth provided, non -matching age and DOB, 
different first and last name [CONTACT_259593], with no explanation), note in their study 
record that they should be excluded from outcome analyses.  Do not mail compens ation for 
survey completion if they can’t be reached for verification.   
7. After final dataset is received from Datatope, review all records for incoherent responses to 
open -ended questions on baseline & follow -up surveys. Flag these records for manual review  to 
check for data quality (e.g, evidence of straightlining, unusual responses).  
8. In cases where deception is suspected but cannot be confirmed, add participant ID to database 
of participants whose inclusion will be adjudicated by [CONTACT_259591].  Include note providing all reasons why deception is suspected, along with any evidence 
that might indicate that the participant’s data are valid.  
 